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ABSTRACT
Breast cancer is a leading cause of premature mortality among women in the
United States. Breast cancer screening tests can help with detecting breast cancer in
early stages and thereby reducing the breast cancer mortality risk. However, due to the
imperfect nature of screening tests, there is always some associated overdiagnosis, false
positives, and false negatives risks. Therefore, to improve breast cancer preventive
care, we defined the focus of this dissertation on modeling breast cancer screening
decisions.
Breast cancer overdiagnosis is the first issue that is addressed in this dissertation.
Although overdiagnosis is known to be the major risk inherent in mammography
screening; currently there is no way to distinguish between overdiagnosed cancers
and the ones that would cause problems over a patient’s lifetime. Overdiagnosis risk
significantly depends on a patient’s compliance with screening recommendations. In
Chapter 2, we use a stochastic framework to perform a harm-benefit analysis to compare
the overdiagnosis risk with the benefits that breast cancer screening provides. In
addition, we estimate the lifetime mortality risk of breast cancer while considering the
overdiagnosis risk and the uncertainty in a patient’s adherence behavior. Our results
show that, although overdiagnosis rate is relatively high in breast cancer screening,
the benefits of breast cancer mammography screening outweigh the overdiagnosis risk.
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The second issue that is addressed in this dissertation is false negative results
caused by density of breast tissue. Breast density is known to increase breast cancer
risk and decrease mammography screening sensitivity. Breast density notification laws,
require physicians to inform women with high breast density of these potential risks.
The laws usually require healthcare providers to notify patients of the possibility of
using more sensitive supplemental screening tests (e.g., ultrasound). Since the enactment of the laws, there have been controversial debates over i) their implementations
due to the potential radiologists bias in breast density classification of mammogram
images and ii) the necessity of supplemental screenings for all patients with high breast
density. Breast density is a dynamic risk factor. Therefore, in the third chapter, we
apply a hidden Markov model (HMM) on a sparse unbalanced longitudinal data to
quantify the yearly progression of breast density based on Breast Imaging Reporting
and Data System (BI-RADs) classifications.
In Chapter 4, we use the results from previous chapter to investigate the
effectiveness of supplemental screening and the impact of radiologists’ bias on patients’
outcomes under the breast density notification law. We consider the conditional
probability of eventually detecting breast cancer in early states given that the patient
develops breast cancer in her lifetime and the expected number of supplemental tests
as patient’s outcome. Our results indicate that referring patients to a supplemental
test solely based on their breast density may not necessarily improve their health
outcomes and other risk factors need to be considered when making such referrals.
Additionally, average-skilled radiologists’ performances are shown to be comparable
with the performance of a perfect radiologist.
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CHAPTER 1
INTRODUCTION
1.1 Background
Breast cancer is the most common non-cutaneous cancer among women in the
U.S. [1]. It is currently estimated that a woman’s lifetime risk of developing breast
cancer is 1 in 8 [2]. In 2020, an estimated 276,480 new cases of invasive breast cancer,
and 48,530 new cases of non-invasive (in situ) breast cancer will be diagnosed in the
U.S. [1]. Moreover, breast cancer is one of the leading causes of death in women with a
lifetime mortality risk of 1 in 38 [1]. Based on the estimates from the American Cancer
Society (ACS), approximately 42,170 women will die as a result of breast cancer in
2020 [1]. Breast cancer screening tests, the most common of which is mammography,
can help with detecting breast cancer in early stages and thereby reducing the breast
cancer mortality risk by treating patients when they have a higher survival chance.
However, due to the imperfect nature of mammography screening, there is always
some associated overdiagnosis, false positives, and false negatives risks. Overdiagnosis
should not be confused with false-positive results. In a false-positive test result, the
disease is mistakenly believed to be present in the patient’s body based on the initial
test. A more accurate follow-up test (e.g., biopsy), however, falsifies the initial belief.
In overdiagnosis, however, the disease is truly present in the patient’s body, but it
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would not cause any harm if remained undetected. False negative rates are especially
higher in women with dense breasts due to the reduced sensitivity of mammography
caused by the masking effect of high density breast tissue. These risks and benefits
of screening tests are functions of each patient’s features such as patient’s adherence,
age, breast density, and family history. Thus, a screening policy which is tailored to
the different features of individuals are desirable.

1.2 Objectives
The fundamental purpose of decision modeling is to provide a methodology
for comparing a set of choices or strategies by calculating the expected value of a
specific outcome resulting from those strategies. One of the main application of
decision analysis is in preventive healthcare modeling which provides a mechanism
for evaluating different preventive strategies using multiple outcome criteria such
as life expectancy, quality of life, and costs. Thus, the purpose of this dissertation
is to evaluate the preventive healthcare decisions for breast cancer which includes
evaluating cancer screening policies in order to diagnosis the disease before its effect on
the patient’s life is irreversible. For this comparison, we consider different factors such
as patient’s adherence, age, breast density, family history, and risk of overdiagnosis.

1.3 Dissertation Organization
A detailed outline of this dissertation is presented below.
Chapter 2 addresses the problem of overdiagnosis in breast cancer screening.
Overdiagnosis risk significantly depends on a patient’s compliance with screening
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recommendations. Specifically, we use two partially observable Markov chains developed by Molani et al. [3] to perform a harm-benefit analysis in order to compare
the overdiagnosis risk with the benefits that breast cancer screening provides. In
this chapter, we also estimate some other criteria such as the expected number of
cancers detected and overdiagnosed, and the expected number of lives saved through
mammography screening. Additionally, we estimate the breast cancer lifetime mortality
risk and compare the results with the lifetime mortality risk reported by American
Cancer Society(ACS) for some in-practice policies.
In chapter 3, we review and apply some of the hidden Markov model parameter
approximation methods to estimate breast density transition probabilities using
mammography screening data from Louisiana Cancer Prevention and Control Programs
[4]. Breast density is defined as the prevalence of fibroglandular tissue in the breast
and is categorized into four categories. Higher breast density can significantly reduce
the mass detection rate since the normal tissues in dense breasts appear as bright
areas in mammography. Breast density is also associated with increased risk of breast
cancer [5]. In addition, due to the lower sensitivity of screening mammography in
women with dense breasts, the cancer is more likely to remain undetected. Breast
density is a dynamic risk factor and typically decreases as a patient becomes older.
Therefore, in this chapter, we use a frequentest method (Baum-Welch) to quantify
the dynamics of breast density. The results of this chapter will be used in the next
section of dissertation to evaluate breast cancer screening policies considering breast
density as an important breast cancer risk factor.

4
Chapter 4 addresses the controversy over breast density notification law and
its potential unintended consequences as well as quality of its implementation. These
laws generally require physicians to inform women with high breast density of their
potential increased risk of breast cancer and the impact of high breast density on
the sensitivity of mammogram test. The laws usually require healthcare providers
to notify patients of the possibility of using more sensitive supplemental screening
tests such as magnetic resonance imaging (MRI) and ultrasound. In this study, we
formulate a finite-horizon, discrete time partially observable Markov chain (POMC)
to investigate the efficacy of supplemental screening and the impact of radiologist’s
behavior and expertise on patients’ outcomes. The patients’ outcome measures include
the conditional probability of eventually detecting breast cancer in early states given
that the patient develops breast cancer in her lifetime and the expected number of
supplemental tests.
Chapter 5 presents some concluding remarks of the research presented in this
dissertation, as well as future work for improving the models presented.

CHAPTER 2
HARM-BENEFIT ANALYSIS OF BREAST CANCER
SCREENING CONSIDERING OVERDIAGNOSIS RISK
AND PATIENT’S ADHERENCE
2.1 Introduction
Although mammography screening reduces breast cancer mortality risk, there
has been increasing concerns that it unintentionally leads to overdiagnosis by identifying
small, indolent, or regressive breast tumors that would not otherwise become clinically
apparent. Overdiagnosis occurs when breast cancer is detected during a routine screening mammogram, yet the cancer would never have presented clinically in the absence of
screening. Overdiagnosis results from the current inability of physicians to determine
if a patient diagnosed with breast cancer will or will not eventually develop any breast
cancer related complications or symptoms over the course of her lifetime. Therefore,
the standard treatment is administered to all patients whose cancer has been detected.
For the overdiagnosed patients, however, this treatment is unnecessary and results
in patients’ overtreatment. These patients go on to experience unnecessary medical
intervention, financial costs, and psychological stress due to being overdiagnosed. The
impact of overdiagnosis on patients’ well-being and physical health is life-long and
thus, overdiagnosis and its subsequent unnecessary treatment that comes along with
different risks are the most important potential harms of mammogram screening [6].
5
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Overdiagnosis should not be confused with false-positive results. In a falsepositive test result, the disease is mistakenly believed to be present in the patient’s
body based on the initial test. A more accurate follow-up test (e.g., biopsy), however,
falsifies the initial belief. In overdiagnosis, however, the disease is truly present in the
patient’s body, but it would not cause any harm if remained undetected.
Quantifying overdiagnosis risk is very challenging as overdiagnosis cannot be
observed directly. The main reason is the administration of treatment upon cancer
detection which makes it impossible to directly determine the risk. Therefore, there is
a wide variation on the estimation of the extent at which breast cancer overdiagnosis
occurs. Various clinical trials, each with different sets of assumptions, have been
applied to indirectly estimate the overdiagnosis risk. Dominant research methods that
have been used to measure overdiagnosis are cohort, and follow-up of randomized
controlled trials (RCTs) studies [7], which require a long follow-up of the patients for
accurate quantification of overdiagnosis. These studies, however, are prone to bias in
estimation of overdiagnosis due to the limitation in their designs and assumptions.
According to the independent UK panel on breast cancer screening [8], potential bias
(e.g., suboptimal randomization), uncertainty in the relevance of old trials to current
screening programs, and the unavailability of some key information in such trials are
some of the main reasons that make these estimations unreliable. Lee and Etzioni
[9] conclude that for generating reliable estimates for overdiagnosis, one needs to
recognize limitations which include the problems of unknown counter-factual incidence,
insufficient follow-up time, and trial design limitations.
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There are a limited number of studies that use mathematical/statistical
modeling for estimation of overdiagnosis. These studies use modeling frameworks for
estimation of overdiagnosis to overcome the limitations in RCTs and cohort studies.
These studies, however, are limited in their assumptions of patients’ compliance with
a screening policy. Adherence is an important, but often ignored, aspect of disease
screening. The World Health Organization (WHO) defines adherence behavior as
“the extent to which a person’s behavior (e.g., taking medication, following a diet,
executing lifestyle changes) corresponds with agreed recommendations from a health
care provider" [10]. Currently, the WHO estimates the adherence rate of patients to all
health care recommendations at roughly 50% in developed countries [10]. In terms of
mammography screening, adherence behavior refers to a patient’s level of compliance
with a screening policy, i.e. showing up to prescribed mammography tests. A study by
the Centers for Disease Control and Prevention (CDC) shows that in 2010, only 66.5%
of women had a mammogram within the past two years [11]. In another study by the
U.S. Preventive Services Task Force (USPSTF), approximately 66% of women aged 40
years and older have had a screening mammography within the past two years [12]. In
addition, based on the 2018 ACS statistics, 50% of U.S. women 40 years of age and older
reported having had a mammogram within the past year and 64% reported having had
a mammogram in the past two years [13]. Given the current screening guidelines in
the U.S. (i.e., annual or biennial mammogram screenings depending on the patient age
and breast cancer risk), the reported compliance rates are considered relatively low. As
undergoing a screening test is a necessary step in occurrence of overdiagnosis, screening
compliance rate should not be ignored in the quantification of overdiagnosis risk.
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Incorporating adherence behavior provides a more realistic estimation of overdiagnosis
and helps the decision makers to better evaluate and compare screening policies.
Besides overdiagnosis and its subsequent unnecessary treatment, false positives,
unnecessary biopsies, and radiation exposure are other risks associated with screening
mammography. These potential risks have led to much debate regarding mammography
screening recommendations. On the other hand, the impact of mammogram in
detecting cancer in its early stages and subsequently increasing survival rates makes
the judgment about the necessity and frequency of mammogram screening challenging.
There are multiple health agencies in the U.S. including the American Cancer Society
(ACS), the United States Preventive Services Task Force (USPSTF), and the American
College of Radiology (ACR), which recommend different breast cancer screening
guidelines. Currently, there is not even an established consensus regarding the starting
age, the stopping age, or the interval between two consecutive mammography screenings
due to the uncertainty regarding the balance in benefits and harms associated with
mammography screening.
In this chapter, we use a stochastic modeling framework developed by Molani
et al. [3] to perform a harm-benefit analysis for overdiagnosis risk and estimate the
ratio of detected cancers that are overdiagnosed, the ratio of lives saved per each
overdiagnosed case, and other measures of interest for several screening policies.
Molani et al. [3] quantified the overdiagnosis risk associated with different breast
cancer screening policies while incorporating the uncertainty in women’s adherence
behaviors. Often, calculation of overdiagnosis is based on the excess incidence (EI) in a
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screened population compared to an unscreened reference population during the screening period. Overdiagnosis is usually reported as the proportion of screen-detected cancers which do not cause harm if left undetected. In this study, they introduced different
measures of overdiagnosis risk. In addition to the previously commonly used measure,
i.e., the ratio of number of overdiagnosed cases to the number of screen-detected
cancers, they estimated the lifetime overdiagnosis risk. The lifetime overdiagnosis risk
measures the risk of overdiagnosis imposed on patients if they follow a screening policy
over their lifetime. Additionally, they estimated breast cancer stage-specific and agespecific risk of overdiagnosis, that gives the conditional risk of overdiagnosis given that
a patient is diagnosed at a specific age and/or a specific cancer stage. Unlike cohort and
RCT studies which are prone to different biases (as discussed above) and are limited
to assess the overdiagnosis risk for only one policy that is applied to the screened arm,
the proposed framework can assess different overdiagnosis risks for any given policy.
In addition, the proposed model takes into consideration the uncertainty in patients’
compliance to provide a realistic estimation of the risk. In this study, two partially
observable Markov chain models are developed to estimate overdiagnosis measures
of interest. The first partially observable Markov chain model represents women’s
adherence behaviors, and the second one represents natural history of breast cancer.
The remainder of this chapter is as follows. In Section 2.2, we present our
proposed model for estimation of breast cancer mortality risk and a harm-benefit
analysis framework. Section 2.3 presents the parameter estimations, and the design
of our numerical studies. In Section 2.4, we present the results. We summarize and
conclude in Section 4.6.

10
2.2 Model Formulation
In this section, we review the partially observable Markov chains developed
by Molani et al. [3] to model patients’ adherence behaviors and breast cancer natural
history. The modeling of adherence behavior, which is detailed in Section 2.2.1,
provides a framework to calculate age-specific probabilities of patients’ compliance
with a prescribed mammogram screening. Using the adherence model and the breast
cancer natural history model, we formulate a framework to estimate the breast cancer
mortality risk considering overdiagnosis and a harm-benefit framework to analyze the
harm-benefit trade-off under different breast cancer screening policies.
2.2.1 Adherence Behavior
To model the uncertainty in adherence behavior, patients are classified into
two distinct groups based on the CISNET definition: regular screeners and irregular
screeners. A regular screener is a patient whose mean time between two consecutive
screenings is less than or equal to 2 years. An irregular screener is a patient whose
mean time between two consecutive screenings is greater than 2 years. However, a
patient’s classification is not static as adherence behavior can change over time. It has
been shown that a patient’s age, past screening behavior, education level, income level,
and perceived risk are all influential factors in mammography screening adherence
[14]. Therefore, a patient’s adherence behavior is subject to change as these influential
factors change.
A discrete-time partially observable Markov chain was developed to model
a patient’s adherence behavior. Figure 2.1 shows the state transition diagram of
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the proposed Markov chain modeling a patient’s adherence behavior. A partially
observable model is used due to the uncertainty in characterizing a patient’s compliance
with a screening recommendation. From this model, we can determine the probability
that a patient complies with a policy prescribed screening at any age. The probability
of compliance with a policy’s prescribed mammography is then used in Section 2.2.2 to
calculate adherence-adjusted overdiagnosis risks. The following is the list of notations
used in the model.

Regular

Irregular

Figure 2.1: State transition diagram of the underlying adherence behavior Markov
model
• t: Time period, t = 0, 1, · · · , T . We model a patient’s adherence behavior
starting at age 40 (t = 0). We account for possible behavioral changes every six
months, and the modeling ends at age 100 (t = T = 120).
• sb : Core adherence behavior state, sb ∈ Sb = {R, I}. The two adherence core
states correspond to the two types of screeners: regular (R) and irregular (I).
The states are partially observable as the decision maker does not have full
information about a patient’s adherence behavior.
• Tt (s0b |sb ): Core adherence behavior state transition probabilities, that is, the
probability of a patient being in state s0b at time t + 1 given that she was in state
sb at time t.
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• at : Prescribed action at time t, at ∈ A = {M, W }, where M and W represent
action mammogram and wait, respectively.
• Oat : Observation space, which includes observations seen upon taking action
at at time t. If at = M , the observation at time t is ot ∈ OM = {c, c̄}, where
c represents compliance with the prescribed mammography, and c̄ represents
failure to comply. If at = W , then no observation will be received and OW = ∅.
• Qt (ot |at , sb ): Observation probabilities, which represent the probability of
receiving observation ot given that the patient is in state sb and action at
is taken at time t.
• ht : Screening attendance history up to time t, ht = (a1 , o1 , a2 , o2 , . . . , at−1 , ot−1 ) ∈
Ht , where Ht is the set of all possible screening attendance sample paths.
• κht : History dependent adherence behavior belief state, κht = [ κht (R), κht (I)] ,
where κht (R) and κht (I) represent the probability of being in core adherence state
R and I, respectively, given the patient history of compliance to recommended
screenings is ht .
• βt : Expected adherence behavior belief state at time t, βt = [ βt (R), βt (I)],
where βt (R) and βt (I) represent the probability of being in core adherence state
R and I, respectively.
A patient’s adherence behavior belief is updated based on the observations received at the time epochs where the prescribed action is to undergo a mammogram and
a patient screening history. If the screening policy does not prescribe a mammogram,
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the adherence behavior belief state is updated based on the core adherence state transition probabilities to account for adherence behavior dynamics. Given the adherence
behavior belief state distribution associated with sample path ht at time t is κht , Equation (2.1) calculates the updated adherence behavior belief state when the prescribed
action is at and observation ot is received. More specifically, κht+1 (s0b |κht , at , ot ) gives
the probability that the patient is in adherence state s0b at time t+1, given her adherence
belief up to time t is κht , action at is taken and observation ot is received at time t.

κht+1 (s0b |κht , at , ot ) =










sb =R,I









P

P

κht (sb )·Qt (ot |M,sb )·Tt (s0b |sb )

P

κht (sb )·Qt (ot |M,sb )

,

at = M,

ot ∈ OM ,

sb =R,I

sb =R,I

κht (sb ) · Tt (s0b |sb ) ,

at = W.
(2.1)

The first line in Equation (2.1) represents the case when the recommended
action is a mammogram test. In such case, we use Bayes rule to update the belief about
the patient being a regular or irregular screener based on the received observation ot
at time t. The second line in Equation (2.1) represents the case when the prescribed
action is to wait, in which case the dynamics of adherence behavior is used to update
the adherence behavior belief states.
Let P (ht ) denote the probability associated with the screening attendance
sample path ht . The probability of sample path ht can be calculated recursively as
follows:
P (ht ) = P (ht−1 ) · Qt (ot |at ),

(2.2)
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where P (h0 ) = 1 since there is no uncertainty associated with a sample path when no
action is taken, yet. In addition, Qt (ot |at ) =

P

sb =R,I

κht (sb ) · Qt (ot |at , sb ).

The expected adherence behavior belief state (the average over all possible
screening attendance sample paths) at time t and the probability that a patient
complies with a policy prescribed screening at time t can be calculated according to
Equations (2.3) and (2.4), respectively.
βt =

κht · P (ht ),

(2.3)

Qt (c|at , sb ) · βt (sb ),

(2.4)

X
ht ∈Ht

Ct =

X
sb =R,I

where βt is calculated by taking into consideration all possible screening attendance
sample paths up to time t, and Ct is calculated based on the prescribed action at time
t using the total probability rule.
2.2.2 Overdiagnosis Risk Estimation
A discrete-time partially observable Markov chain model was developed to
characterize the natural history of breast cancer. A partially observable model is
developed because mammography screening is imperfect and provides only partial
information about the core health state of a patient. In this model, three breast
cancer health states are included: early stage, advanced stage, and symptomatic breast
cancer. This Markov model was proposed by Maillart et al. [15], which is based on
the American Joint Committee on Cancer (AJCC) classification, with some minor
changes to develop our POMC model. We consider early stage breast cancer to be
the grouping of stage 0, stage I, and stage II without lymph node involvement. We
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consolidate stage II with lymph node involvement, stage III, and stage IV breast
cancer into the single health state of advanced breast cancer. Further, we assume
that the manifestation of symptoms is only possible from the advanced stage of the
disease. Based on this model, cancers take at least one year from their onset to grow
to a symptomatic size (given the time interval between two epochs is six months).
This is in line with previous studies and reports since even the cancer with the highest
progression rates cannot grow from a cell to a symptomatic size in six months [16].

Healthy
(1)

Early Breast
Cancer
(2)

Death from
Other Causes
(6)

Advanced
Breast Cancer
(3)

Symptomatic
Breast Cancer
(4)

Death from
Breast Cancer
(5)

Figure 2.2: State transition of the underlying health Markov model representing the
natural history of breast cancer
The following is the list of the notations used in this section. Note that notation
t and at are defined previously in Section 2.2.1 and will be used here.
• sh : Core health state, sh ∈ Sh = {1, 2, · · · , 6}, where the state space Sh is
composed of six states: healthy (1), early breast cancer (2), advanced breast
cancer (3), symptomatic breast cancer (4), death from breast cancer (5), and
death from other causes (6). Due to the imperfect nature of mammography
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screening, states 1, 2, and 3 are partially observable. All other states are fully
observable.
• Pt (s0h |sh ): Core health state transition probability, which represents the probability that a patient is in state s0h at time t + 1 given she was in state sh at time
t.
• Θat : Observation space when the prescribed action is at . At each time period, an
action dependent observation will be received. If at = M , then the observation
at time t will be θt ∈ ΘM = {M + , M − }, where M + and M − represent positive
and negative mammogram result, respectively. If at = W , then no observation
will be received, and ΘW = ∅.
• Kt (θt |at , sh ): Observation probabilities which represent the probability of receiving observation θt given action at is taken, and the patient is in state sh at
time t. Note that Kt (M + |M, sh ) is the sensitivity of mammography screening
for early stage (sh = 2) and advanced stage (sh = 3) breast cancer at time t.
Further, Kt (M − |M, sh = 1) is the specificity of mammography test at time t.
• χt : History of screening results up to time t, χt = (a1 , θ1 , . . . , at−1 , θt−1 ) ∈ Xt ,
where Xt is the set of all possible screening results’ sample paths.
• ηχt : History dependent health belief state, which represents the probability
distribution of a patient being in the partially observable core health states given
the screening results history χt , i.e., ηχt = [ηχt (1), ηχt (2), ηχt (3)] . Note that
ηχt (sh ) represents the probability of being in health state sh given the screening
results history χt .
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• πt : Expected health belief state, πt = [πt (1), πt (2), πt (3)] , where πt (sh ) represents
the probability of being in the core health state sh at time t.
At each time epoch t, one of the two possible actions of screening mammogram
or wait is prescribed by a policy. When the prescribed action is a mammogram,
patients may follow the prescribed mammogram or skip it (i.e., wait). We assume
actions are taken at the beginning of each period. Regardless of the action taken, we
account for possible incidence and progression of breast cancer. If a patient undergoes
a mammogram and receives a positive result, we assume a biopsy will be performed
to confirm the presence of cancer. Upon cancer detection, the patient will not receive
screening any longer. We assume no treatment is administered upon cancer detection
to estimate overdiagnosis. However, we follow up the patient up to time T to determine
if the patient dies from breast cancer or other causes to calculate the overdiagnosis risk.
The health belief state of a patient at each time epoch t is updated based on
the action taken and the observation received. Let τ [ηχt , at , θt ] denote the updated
health belief state for sample path χt+1 given that at time t the health belief state
is ηχt , action at is taken and observation θt is received. We have
ηχt+1 (s0h ) = τ [ηχt , at , θt ](s0h ) =

3
P


ηχt (sh )·Kt (M − |M,sh )·Pt (s0h |sh )



sh =1

1

,

3

Lt
P


ηχt (sh )·Kt (M − |M,sh )



sh =1















1
P (s0 |s
Lt t h h
1
Lt

3
P
sh =1

= 1),

ηχt (sh ) · Pt (s0h |sh ) ,

at = M, θt = M − ,
at = M, θt = M + , sh = 1,
at = W,

(2.5)
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where Lt is a normalizing factor and represents the probability that the patient survives
time t. The first line in Equation (2.5) represents the case when the patient undergoes
a prescribed mammogram and receives a negative result. In such case, we use Bayes
rule to update the patient’s health belief state based on the received result. The
second case represents the situations in which the patient receives a false positive
mammogram result (that is, the patient receives a negative biopsy after receiving a
positive mammogram result). In this case, the patient’s belief state is updated by
considering possible cancer development from the cancer-free state at time t (i.e.,
sh = 1 at time t). When the prescribed action is to wait, we use the dynamics of
breast cancer natural history to update our belief about the patient’s health status.
This is represented in the third case of Equation (2.5).
Similar to the adherence behavior model, the probability of each sample path
can be calculated as P (χt+1 ) = P (χt ) · K(θt |at ), where K(θt |at ) =

P3

sh =1

Kt (θt |at , sh ) ·

ηχt (sh ). Therefore, the expected health belief state can be calculated as follows.
πt =

X

ηχt · P (χt ).

(2.6)

χt ∈Xt

For an overdiagnosis to happen, a cancer needs to be detected first. This
requires that (i) the patient is in one of the cancer states, (ii) the patient shows
up to a prescribed mammogram screening, and (iii) the screening mammography
detects the cancer. The probabilities of events (i) and (iii) depend on the patient’s
cancer stage. The probability of event (ii), however, is independent of the cancer
stage as the patient has no information about the presence of cancer in her body and
decides independently about attending a prescribed screening. Let Dt (sh , at ) denote
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the probability of detecting a cancer in state sh , (sh = 2, 3) at time t when action at
is taken. Equation (2.7) calculates this probability.

Dt (sh , at ) =







πt (sh ) · Ct · Kt (M + |M, sh ),

at = M,






0,

at = W.

(2.7)

Moreover, let ωt (sh ) denote the conditional probability that a patient with a
breast cancer in state sh (sh = 2, 3) at time t eventually dies from other causes without
developing symptomatic breast cancer. Equation (2.8) calculates this probability for
early stage breast cancer and comes from the following logic. Given that the patient
has early breast cancer at time t, she can die from other causes in time period t, or
she can survive time t and eventually die from other causes. Note that if the patient
survives time t, she either stays in early breast cancer or progresses to advanced breast
cancer at time t + 1.
ωt (2) = Pt (6|2) +

X

Pt (sh |2) · ωt+1 (sh ).

(2.8)

sh =2,3

Following the same logic, Equation (2.9) calculates the probability that a
patient who is in advanced breast cancer at time t eventually dies from other causes
without developing symptomatic breast cancer.
ωt (3) = Pt (6|3) + Pt (3|3) · ωt+1 (3).

(2.9)

At the final age, we assume a patient eventually dies from other causes with
certainty due to age-related diseases and co-morbidities. Therefore, ωT (2) = ωT (3) = 1.
Note that we assume T = 120, which represents the age of 100.
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Next, we estimate age-specific and stage-specific overdiagnosis risk, Ωt (sh ),
which calculates the probability of overdiagnosis if a patient is diagnosed with breast
cancer in stage sh at time t. This includes the probability of both detecting breast
cancer at time t and the probability of eventually dying from other causes before
developing symptomatic breast cancer; that is
Ωt (sh ) = Dt (sh , at ) · ωt (sh ).

(2.10)

To compute age-specific overdiagnosis risk, we note that detection of early
breast cancer and detection of advanced breast cancer are mutually exclusive events.
Thus the probability that a patient, who is diagnosed with breast cancer at time t is
overdiagnosed can be calculated as follows:
Ωt =

3
X

Ωt (sh ) .

(2.11)

sh =2

Over her lifetime, a patient’s breast cancer can be diagnosed at any age.
However, screening stops once breast cancer has been detected. Therefore, a patient
cannot be diagnosed at two distinct ages. Hence, the lifetime overdiagnosis risk of a
screening policy can be obtained as follows:
Ω=

T
X

Ωt .

(2.12)

t=0

2.2.3 Harm-Benefit Analysis
A harm-benefit analysis framework is presented to quantify the harms’ and benefits’ trade-off for different screening policies. More specifically, we investigate the associated harms and benefits of applying a screening policy to the U.S. female population
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and measure the expected number of cancers detected and overdiagnosed, as well as the
expected number of lives saved through mammography screening. Let nαt denote the
U.S. female population size at age αt , αt = 40, 40.5, . . . , 100. Note that patient age and
time period t are related through αt = 0.5t+40, (t = 0, . . . , 120). The expected number
of screen-detected cancers and the expected number of detected cancers that lead to
overdiagnosis are calculated as

P120

t=0

nαt ·

P

sh =2,3

Dt (sh , at ) and

P120

t=0

nαt · Ωt , respec-

tively. The expected number of screen-detected cases who survive breast cancer is calculated as

P120

t=0

nαt · SRαt , where SRαt is the probability of detecting a cancer through

screening at age αt that will be cured with treatment and is calculated as follows:
SRαt =

X

Dt (sh , M ) · γαt (sh ),

(2.13)

sh =2,3

where γαt (sh ) is the probability that a patient diagnosed with cancer stage sh at age αt
survives breast cancer and eventually dies of a competing cause given that treatment
is administered upon cancer detection.
2.2.4 Lifetime Breast Cancer Mortality Risk
In this section, we present a framework to estimate the breast cancer lifetime
mortality risk derived from the proposed model. Let ψta (ηχt ) denote the probability
that a patient with a screening history χt and expected health belief state ηχt eventually
dies from breast cancer when action at is taken at time t. If the recommended action
at time t is to wait (W ), the patient risk of eventually dying from breast cancer is
calculated as follows:
ψtW (ηχt )



= ηχt (3)·Pt (4|3)·rt+1 (4)+ 1−

3
X
sh =1



a
ηχt (sh )·Pt (6|sh ) ·ψt+1
(τ [ηχt , W, .]), (2.14)
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where rt+1 (4) is the probability that a patient diagnosed with symptomatic cancer
(sh = 4) at time t + 1 eventually dies of breast cancer. The logic of Equation (2.14)
is as follows. If the patient is in advanced cancer state at time t, she may proceed to
symptomatic cancer within period t with probability Pt (4|3) and eventually die from
breast cancer with probability rt+1 (4), or she may survive to the next period in which
case her belief state for time t + 1 is updated and her probability of eventually dying
from breast cancer is calculated recursively. The updated expected health belief state,
ηχt+1 , can be calculated based on the third case in Equation (2.5).
If the prescribed action at time t is a mammogram screening, the probability
that the patient eventually dies of breast cancer is
a
ψtM (ηχt ) = ηχt (1) · K(M + |M, sh = 1) · (1 − Pt (6|1)) · ψt+1
(τ [ηχt , M, M + ])

+

X

ηχt (sh ) · K(M + |M, sh ) · rt (sh )

sh =2,3

+ ηχt (3) · K(M − |M, sh = 3) · Pt (4|3) · rt+1 (4)
+

 X

ηχt (sh ) · K(M − |M, sh ) · (1 − Pt (6|sh ))

sh =1,2



a
+ ηχt (3) · K(M |M, sh = 3) · Pt (3|3) · ψt+1
(τ [ηχt , M, M − ]).
−

(2.15)

The logic of Equation (2.15) is as follows. Assume that the mammography
result is positive. Two cases are possible: (i) The true health state of the patient
is cancer-free (sh = 1), in which case the follow-up biopsy reveals that the initial
mammogram positive result was inaccurate. In this case, the patient survives period t
with probability (1 − Pt (6|1)), her health belief is updated using the second case in
Equation (2.5), and her risk of dying from breast cancer in the future is calculated
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recursively. (ii) The patient is in one of the cancer states, in which case the patient
starts treatment upon receiving a positive result, and her risk of eventually dying
from breast cancer would be rt (sh ) depending on the cancer status (sh = 2, 3). Note
that we do not model the treatment explicitly. We assume that the patient leaves
the model when cancer is detected. If the mammogram screening result is negative,
two cases are possible: (i) the patient develops some symptoms when in advanced
breast cancer state (sh = 3), in which case she proceeds to treatment and her risk of
eventually dying from breast cancer would be rt+1 (4). (ii) She survives time epoch t
with probability (1 − Pt (6|sh )) when in states sh = 1, 2 and with probability Pt (3|3)
when in advanced breast cancer (sh = 3). In such case, the patient health belief is
updated based on Equation (2.5), and her mortality risk is calculated recursively to
account for the future risk of dying from breast cancer.

2.3 Numerical Analysis
2.3.1 Model Input
The data sources that are used in the model parameters’ estimation are listed
in Table 2.1. Estimation of the core health state transition probabilities is the most
challenging due to the lack of a single data source that includes all the age-specific
dynamics of untreated, unscreened natural history of breast cancer. We, therefore,
use several sources to estimate the breast cancer dynamics parameters [15, 17, 18].
Our primary source for the core health transition probabilities estimations is Maillart
et al. [15]. However, since the breast cancer natural history model presented here is
more detailed and includes symptomatic cancer, we use some additional sources for
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parameters’ estimation. The age-specific non-breast cancer induced death probabilities,
that is Pt (6|sh ) for sh ∈ Sh \ {5, 6}, are calculated based on the 2010 report on
annual mortality rate from all causes of death by the CDC [19]. We use the same
approach proposed by Maillart et al. [15] to estimate these probabilities. The transition
probabilities for the healthy state, Pt (sh |1) for sh = 1, 2, are also adopted from Maillart
et al. [15]. The probability that an untreated early breast cancer remains in the early
breast cancer state in six months is calculated based on a study by Wu et al. [17], which
reports the likelihood that untreated pre-clinical local breast cancer (P L) remains
pre-clinical local breast cancer over the course of one year, i.e.,

√

P L = Pt (2|2). The

probability of progression of untreated breast cancer from early stage to advanced stage,
Pt (3|2), is obtained using the normalizing condition, i.e., Pt (3|2) = 1−Pt (2|2)−Pt (6|2).
The six-month transition probability from advanced breast cancer to symptomatic
breast cancer, Pt (4|3), is obtained from Bloom et al. [18]. Similarly, the survival
probability of symptomatic breast cancer in six months is estimated based on the
five-year survival probabilities from the onset of symptoms (SF) reported by Bloom
et al. [18], i.e.,

√
SF = Pt (4|4). Although outdated, the Bloom et al. [18] study is

10

a unique source for late stage breast cancer progression modeling. The probability
that an untreated advanced breast cancer remains in advanced breast cancer in six
months, Pt (3|3), and the probability of dying from breast cancer in six month when
in symptomatic breast cancer state, Pt (5|4), are calculated based on normalizing
conditions, i.e., Pt (3|3) = 1 − Pt (4|3) − Pt (6|3), and Pt (5|4) = 1 − Pt (4|4) − Pt (6|4),
respectively.
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Table 2.1 Input data sources for parameters estimation
Model Parameter
Parameter Values Source
Adherence state transition probabilities
Table A.1
National Health Interview Survey [20]
Adherence rates
Table A.2
HINTS [21], and Madadi et al. [22]
Initial adherence belief
Table A.3
National Health Interview Survey [20]
Health state transition probabilities
Table A.4
Maillart et al. [15], Wu et al. [17], and Bloom et al. [18]
Mammography sensitivity
Table A.5
Maillart et al. [15]
Mammography specificity
0.89300
Ayer et al. [23]
Initial health belief
Table A.6
Gail risk model [24]
Survival rate for screen-detected breast cancer by state Table A.7
Maillart et al. [15]
Survival rate for symptomatic breast cancer
0.84427
Allgood et al. [25]
U.S. age composition
Table A.8
U.S. Census Bureau [26]
Breast cancer treatment costs
Table A.9
Mariotto et al. [27], and Ong and Mandl [28]

The transition probabilities of the adherence behavior model, Tt (s0b |sb ), are
estimated using the CDC 2015 National Health Interview Survey (NHIS) data. NHIS
dataset includes mammogram participation report of 10, 245 cases over six years.
Adherence to mammography recommendations is shown to be correlated with age
[29, 30]. To calculate the age-specific estimates of adherence transition probabilities,
the survey participants are first filtered by age into one of three age groups: [40 − 50),
[50 − 65), or 65+. These age groups are adopted from previous studies [29, 30]. We use
the first four years of NHIS data to classify survey participants as regular or irregular
screeners based on the screening mammography history. Our analysis shows that
52%, 69%, and 63% of cases in age groups [40 − 50), [50 − 65), and 65+ are regular
screeners, respectively. We then calculate the proportion of subjects who maintain
their classification (stay a regular (irregular) screener if first identified as a regular
(irregular) screener) based on the remaining data from the last two years. Let FR
and FI denote the proportion of patients who maintained their classifications as a
regular screener and irregular screener in the last two years, respectively. FR and FI
can be interpreted as the two-year transition probabilities from regular to regular
and irregular to irregular screener, respectively. To estimate the six-month transition
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probabilities, we account for all possible sample paths a patient can take. Equations
(2.16) and (2.17) represent all possible six-month transitions sample paths and their
relations to FR and FI . Using Equations (2.16) and (2.17) along with the normalizing
conditions T (R|R) + T (I|R) = 1, and T (R|I) + T (I|I) = 1, we can calculate all the
four transition probabilities. Note that we assume that patients in each age group
have similar adherence behavior dynamics. Therefore, we drop the time subscripts for
the transition probabilities for the sake of notational simplicity.
FR = T (R|R)4 + 3 · T (R|R)2 · T (I|R) · T (R|I)
+ 2 · T (R|R) · T (I|I) · T (I|R) · T (R|I)

(2.16)

+ T (I|I)2 · T (I|R) · T (R|I) + T (I|R)2 · T (R|I)2 .
FI = T (I|I)4 + 3 · T (I|I)2 · T (R|I) · T (I|R)
+ 2 · T (I|I) · T (R|R) · T (R|I) · T (I|R)

(2.17)

+ T (R|R)2 · T (R|I) · T (I|R) + T (R|I)2 · T (I|R)2 .
We estimate FR for the age groups [40-50), [50,65), and 65+ as 0.9361, 0.9169,
and 0.9121, respectively. In addition, we estimate FI for these age groups to be
0.4340, 0.6063, and 0.7644, respectively. The age-specific observation probabilities
for the breast cancer model, Kt (θt |at , sh ), are calculated based on the mammography
test sensitivity and specificity reported in previous studies [15, 23]. The age-specific
observation probabilities for the adherence behavior model, Qt (ot |at , sb ), are adopted
from Madadi et al. [29]. Initial health belief state (risks of early and invasive cancers)
for women aged 40 are estimated using the Gail model [24]. For women at an older
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age, we use Bayesian updating to estimate the health belief state. Initial adherence
belief state at age 40 is estimated using the NHIS data [20]. For the harm-benefit
analysis, we use the U.S. Census Bureau population composition data to calculate
the expected number of cancers detected and the expected number of overdiagnosis
for each age group if screening policies applied to the U.S. female population. The
associated breast cancer treatment costs are also adopted from the literature [27, 28]
to estimate the extent of overdiagnosis and unnecessary overtreatment costs.
2.3.2 Experimental Design
In our numerical studies, we consider 203 distinct screening policies, including
the in-practice policies in the United States as well as some alternative policies with
different starting age, stopping age, and screening intervals. The in-practice policies
include those recommended by the ACS, USPSTF, and ACR. Based on the ACS
guideline, women are recommended to undergo annual screening between the ages
of 45 and 55. After age 55 it is up to the patient to continue the annual screening
or switch to biennial screening. The ACR guideline recommends women undergo
annual mammography screening starting at age 40. The ACS and ACR guidelines do
not specify a stopping age and recommend women undergo mammography screening
as long as they are in good health. Therefore, in this study, we consider different
stopping ages ranging from 70 to 100 with 5-year increments for the ACS and ACR
policies. The USPSTF recommends biennial screening for women aged 50 to 74.
We consider two types of policies in our numerical analysis: static and dynamic
policies. A static policy has a fixed screening interval over the patients’ lifetime and
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is represented as (ab , i1 , ae ), where ab , i1 , and ae are screening starting age, screening
interval length, and screening stopping age, respectively. For example, the USPSTF
policy, which is a static policy, is represented as (50,2,74). In a dynamic policy,
however, the screening interval length changes over the patient’s lifetime to account
for change in the dynamics of breast cancer. A dynamic policy is represented as
(ab , i1 , as , i2 , ae ), where as , i1 , and i2 are the switching age, first and second screening
interval length, respectively, and ab and ae are similar to that of the static policies. For
example, (45,1,55,2,70) is a version of the ACS guideline, which recommends annual
screening between the ages of 45 and 55 and biennial screening between ages of 55
and 70. Table 2.2 shows different screening parameters considered in this study.
Table 2.2 Screening policies considered in the numerical analysis
Policy Start age
Static
40-60
Dynamic
40-60

1st interval
1,2
1,2

Switching age
45-65

2nd interval
1,2

Stopping age
70-100 (5 year increments)
70-100

2.4 Results
In this section, we present the harm-benefit analysis results and lifetime breast
cancer mortality risk for in-practice and some alternative policies.
2.4.1 Harm-Benefit Analysis Results
In this section, the results of the harm-benefit analysis are presented for some
in-practice policies. Specifically, we analyze the harms and benefits associated with
different variations of the ACS, ACR and USPSTF policies. We consider the cohort of
U.S. women aged 40 to 100 and assume that women are screened under each policy. The
expected number of cancers detected, the expected number of overdiagnosed cases, the
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expected number of screen-detected patients who survive breast cancer, and the ratio
of the number of lives saved per each overdiagnosed case are calculated for each policy.
We also analyze the results in terms of the associated unnecessary costs that could be
avoided if patients were identified to be overdiagnosed. The overtreatment cost considered here includes the initial treatment costs spent in the first year of treatment upon
cancer detection. We compare the estimated overtreatment costs with the reported U.S.
annual breast cancer care cost. The proportion of annual breast cancer care cost spent
on overtreatment is reported for each policy. The annual cost of breast cancer care in
2010 was estimated to be $16.50 billion [28]. Note that although we report the results for
one year of screening, we assume patients undergo each policy over their entire lifetime;
that is the overdiagnosis and survival rates are calculated over the patients’ lifetimes.
Tables 2.3 and 2.4 present the harm-benefit analysis results for the adherenceadjusted and perfect adherence case, respectively. Based on the results, about 10%
to 22% of screen-detected cancers for both imperfect and perfect adherence cases are
overdiagnosed which is in-line with the ratios reported by [28]. For both adherenceadjusted and perfect adherence case, the ratio of overdiagnosed cancers to screendetected cancers increases as the screening policy becomes more invasive at older ages,
with the ACS policy with changing screening intervals and stopping age of 70 having
the lowest and the ACR policy with stopping age of 100 having the highest rate of
overdiagnosed cancers to screen-detected cases. In addition, the variation of the ACS
and ACR policies with stopping age of 70 have the highest numbers of lives saved per
overdiagnosed cases. In general, the results support the implementation of screening
for breast cancer preventive care since the expected numbers of lives saved are larger
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than the number of overdiagnosed cases for all the policies considered here. The results
also show that the benefits of screening decrease significantly as the patients become
older. Therefore, organized screening programs are more effective when applied to
women younger than 70 since this group of women has a higher life expectancy and
thus lower risk of being overdiagnosed. The ratios of total annual cost disbursed on
overtreatment are estimated for both annual estimated cost of $16.50 billion reported
in the literature [28] and the expected annual breast cancer care calculated by the
model, which includes both screening and treatment costs. In terms of the associated
overtreatment costs, the ACS and ACR policies with stopping age of 70 and 100 have
the lowest and the highest ratios of overtreatment cost to the total breast cancer care
costs, respectively, which supports stopping screening at the age of 70.
Moreover, comparing the results for the perfect adherence and adherenceadjusted case shows an increase in the expected number of screen-detected breast
cancers and consequently an increase in the expected number of overdiagnosed cases
when assuming perfect adherence. However, for policies with lower stopping age (70
and 74), this increase in the expected number of screen-detected breast cancers mostly
contributes to the number of cases that are not overdiagnosed. Thus, for these policies
when assuming perfect adherence, we have a lower ratio of overdiagnosed cases to
the expected number of detected cancers as well as a higher ratio of lives saved per
overdiagnosed cases, which imply encouraging women to comply with the prescribed
screening policies at younger ages. However, when the policy recommends stopping
screening at an older age, perfect adherence case yields higher ratios of overdiagnosed
cases to screen-detected cases as well as lower expected numbers of lives saved per
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overdiagnosis when compared to the adherence-adjusted case. This happens as the
probability of overdiagnosis in older women is higher. This implies the negative
effects of intense mammography screening at older ages. Moreover, the increase in the
expected number of overdiagnosed cases causes an increase in the overall overtreatment
costs in the perfect adherence case compared to the adherence-adjusted case.

ACR: (40,1,70)
ACR: (40,1,80)
ACR: (40,1,90)
ACR: (40,1,100)
ACS: (45,1,70)
ACS: (45,1,80)
ACS: (45,1,90)
ACS: (45,1,100)
ACS: (45,1,55,2,70)
ACS: (45,1,55,2,80)
ACS: (45,1,55,2,90)
ACS: (45,1,55,2,100)
USPSTF: (50,2,74)

Policy
81491.208
102829.724
113777.342
115302.337
80103.400
101441.917
112389.535
113914.530
76139.111
97399.951
109090.892
110604.081
81629.827

Expected number of
screen-detected BC
8904.079
16471.229
22849.362
23956.860
8891.599
16458.749
22836.882
23944.380
8018.493
15034.767
21490.948
22531.952
11033.332

Expected number
of overdiagnosis

Ratio of overdiagnosed
cases to screen-detected
cases (%)
10.926
16.018
20.082
20.777
11.100
16.225
20.319
21.020
10.531
15.436
19.700
20.372
13.516

Expected number
of lives saved per
overdiagnosis
6.694
4.669
3.756
3.634
6.519
4.573
3.686
3.567
6.518
4.551
3.600
3.486
4.983

Ratio of
Overtreatment to
BC care cost (%)
1.958
3.612
5.000
5.238
1.965
3.620
5.006
5.246
1.901
3.579
5.108
5.352
2.673

Ratio of Overtreatment to
BC care cost
(model-based) (%)
1.715
3.039
4.121
4.307
1.723
3.047
4.129
4.315
1.666
3.000
4.179
4.365
2.297

Table 2.3 Harm-benefit analysis of in-practice policies implemented to the U.S. female population for the adjusted-adherence
case. (BC represents “breast cancer”)
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ACR: (40,1,70)
ACR: (40,1,80)
ACR: (40,1,90)
ACR: (40,1,100)
ACS: (45,1,70)
ACS: (45,1,80)
ACS: (45,1,90)
ACS: (45,1,100)
ACS: (45,1,55,2,70)
ACS: (45,1,55,2,80)
ACS: (45,1,55,2,90)
ACS: (45,1,55,2,100)
USPSTF: (50,2,74)

Policy
160585.013
202362.361
226447.085
230694.572
156870.832
198648.181
222732.904
226980.393
149109.398
190734.669
215999.260
220213.866
159834.618

Expected number of
screen-detected BC
17457.084
32272.335
46452.839
49537.494
17409.910
32225.160
46405.664
49490.319
15700.510
29437.234
43540.736
46440.190
21602.270

Expected number
of overdiagnosis

Ratio of overdiagnosed
cases to screen-detected
cases (%)
10.871
15.947
20.514
21.473
11.098
16.222
20.835
21.803
10.529
15.434
20.158
21.089
13.515

Expected number
of lives saved per
overdiagnosis
6.718
4.683
3.676
3.517
6.520
4.573
3.599
3.444
6.520
4.551
3.521
3.372
4.983

Ratio of
Overtreatment to
BC care cost (%)
3.840
7.079
10.160
10.826
3.848
7.087
10.168
10.834
3.722
7.007
10.344
11.022
5.233

Ratio of Overtreatment to
BC care cost
(model-based) (%)
2.906
5.004
6.921
7.329
2.921
5.024
6.946
7.354
2.822
4.928
6.973
7.380
3.841

Table 2.4 Harm-benefit analysis of in-practice policies implemented to the U.S. female population for the case of perfect
adherence. (BC represents “breast cancer”)
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2.4.2 Lifetime Breast Cancer Mortality Risk Results
Due to the wide variation in the overdiagnosis risk estimations in the literature,
we choose to use a different measure of interest, rather than overdiagnosis, to validate
our model and make sure that the proposed model represents the breast cancer natural
history in the U.S. female population. To do so, we estimate the breast cancer lifetime
mortality risk derived from the proposed model and compare the results with the
lifetime mortality risk reported by ACS for some in-practice policies. We also compare
our results with the estimates provided by two other studies in the literature [15, 22].
The ACS reports a lifetime mortality risk of 1 in 39 (2.57%) [31], which
is calculated based on the mortality data adopted from the U.S. National Cancer
Institute’s Surveillance Epidemiology and End Results (SEER) database from 2010
through 2012. We estimate the lifetime mortality risks for ACR and different variations
of the ACS policies. Table 2.5 shows the results. Note that the screening policy
recommended by the ACS prior to 2015 was similar to the ACR policy (that is,
annual screening starting at age 40). Our estimated lifetime breast cancer mortality
risk for this policy is 3.23%, which is comparable to the ACS report. The 0.54%
difference with the ACS report can be attributed to the fact that our model does not
include other forms of cancer detection such as clinical breast exam (CBE) and breast
self-examination (BSE). Please note that incorporation of CBE and BSE does not
affect the mammography-induced overdiagnosis risk estimation, which is the focus of
this study. This estimate is also comparable with 3.57% estimate reported by Maillart
et al. [15], and 2.56% reported by Madadi et al. [22].
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Table 2.5 Lifetime breast cancer mortality risk for some in-practice policies
Policy
ACR: (40,1,100)
ACS: (45,1,80)
ACS: (45,1,90)
ACS: (45,1,100)
ACS: (45,1,55,2,80)
ACS: (45,1,55,2,90)
ACS: (45,1,55,2,100)

Lifetime breast cancer mortality risk
0.0323
0.0359
0.0349
0.0342
0.0417
0.0413
0.0407
2.5 Conclusion

In this study, we estimate different measures of overdiagnosis risk of mammography screening while incorporating uncertainty in patients’ adherence behaviors. Given
the low rate of compliance with in-practice mammography screening recommendation,
adherence behavior is a necessary factor to include. The measures of overdiagnosis risk
investigated in this study include the common measure of estimation previously
reported in other studies; that is, the proportion of detected cancers that are
overdiagnosed in a screened population, mortality risk considering overdiagnosis,
and overtreatment costs.
We analyze the harm-benefit trade-off of some in-practice policies by measuring
the number of lives that are saved per each overdiagnosed case. We also estimate
the associated proportion of overtreatment cost to breast cancer care cost for each
policy. Our results suggest that policies with stopping age of 70 have higher numbers
of lives saved per overdiagnosed cases. In addition, policies with stopping age 70
have a lower ratio of overtreatment costs to the total breast cancer care cost, which
supports stopping of mammography screening at age 70.
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There are several directions for future work. Given the disparity in incidence
and mortality among different races, future work will include calibrating the models
to determine race-specific overdiagnosis risk. Previous studies on optimal breast
cancer screening did not incorporate the possibility of overdiagnosis. A possible future
direction could be developing an optimization model to derive optimal screening policy
that controls the risk of overdiagnosis.

CHAPTER 3
ESTIMATING TRANSITION PROBABILITY MATRIX
IN A SPARSE UNBALANCED MARKOV CHAIN
3.1 Introduction
Multi-state Markov chain models have been receiving increasing attention in
medical and public health research where health status, responses to treatment, or
dynamic characteristics of a patient are represented by several states. The longitudinal
data collected on patients over time can be modeled as a stochastic process. In
medical longitudinal studies, it is inevitable to encounter missing data because of
patient’s missed scheduled visits, different testing times, and long time interval between
observations. The missingness in longitudinal data could be categorized into two types:
dropouts, where the patient doesn’t show up for a scheduled visit and intermittent
missingness, where patients usually show up only at intermittent visits [32].
The process that governs the likelihood of missingness is called the missing data
mechanism. There are three mechanisms causing missing data: missing completely at
random (MCAR), missing at random (MAR), and missing not at random (MNAR).
In a typical longitudinal data with several individuals, each individual should have the
same number of observations and we record the η th patient’s observation in a T × 1
vector, where T denotes the number of scheduled observations. Let Y = (Y obs ; Y miss )
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denote a T × Γ matrix of T observations for Γ number of patients, where Y obs is
observed values and Y miss is missing observations. In addition, let R denote a T × Γ
matrix indicating whether the tth observation of patient η is missing (rt,η = 1) and 0
otherwise. Assume Υ is a vector of parameters describing the relationship between
missingness, R and the dataset, Y. Based on the definition presented in Laird [33]
and Rubin [34], if the probability of an observation being missing is independent of
the responses, then the data are said to be missing completely at random (MCAR),
P (R|Y obs , Y miss , Υ) = P (R|Υ).

(3.1)

If the probability of missing data only depends on the observed data, then the
missing mechanism is missing at random,
P (R|Y obs , Y miss , Υ) = P (R|Y obs , Υ).

(3.2)

Finally, if the probability of missingness depends on both the missing and
observed values, the mechanism is missing not at random (MNAR),
P (R|Y obs , Y miss , Υ) = P (R|Y obs , Y miss , Υ).

(3.3)

One important concept in analyzing the mechanisms of missing data is ignorability. Ignorability refers to the effect of missingness to the validity of the statistical
inferences. In the MAR and MCAR mechanisms, we do not need to model the
missing data mechanism as a part of the estimation process. On the other hand,
non-ignorable MNAR missingness requires modeling the missing data mechanism to
get good estimates of the parameters [35].
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Missing observations and their effects on estimation of parameters have been
well-studied using two general model-based approaches: Maximum Likelihood and
Bayesian Inference. Maximum likelihood estimation (MLE) which is frequently used
in the literature, obtains parameter estimates by maximizing the likelihood function of
the incomplete data. On the other side, Bayesian inferences on parameters are based
on the posterior distribution of the parameters. To derive a posterior distribution,
prior distributions must initially be assumed for the parameters by sampling the
missing variables through a sampler [36].
Expectation-Maximization (EM) algorithm is a general-purpose approach
to calculate maximum likelihood estimates from incomplete data and has been
proposed by Dempster et al. [37]. This method has been used for different missingness
mechanisms. For example, for ignorable missing mechanism, Sherlaw-Johnson et al.
[38] described expectation-maximization technique for finding the maximum likelihood
estimates for a transition matrix when a system is observed at irregular time intervals.
Craig and Sendi [39] summarized the maximum likelihood estimate of the transition
matrix when the observation intervals have varying length or do not coincide with the
cycle length. They used bootstrap in order to assess the uncertainty of the maximum
likelihood estimate and to construct confidence interval for the transition matrix. Yeh
et al. [32] considered a complete-case analysis using the observed one-step transitions,
a non data-augmentation method (NL) by solving nonlinear equations, and a dataaugmentation method (EM algorithm) for modeling a discrete-time Markov chain
transition probabilities when multiple successive observations are missing at random
between two observed outcomes.
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For the non-ignorable missing mechanism, Troxel et al. [40] proposed a likelihood
method to analyze continuous longitudinal data. They applied the method to a breast
cancer dataset to confirm the non-ignorable missingness mechanism in this dataset.
Albert [41] developed a transitional model for longitudinal binary data and proposed an
EM algorithm for parameter estimation. Chen et al. [42] analyzed the incomplete data
from progressive multi-state disease processes in which individuals are scheduled to be
seen at periodic pre-scheduled assessment times using Maximum likelihood estimation
via an EM algorithm. On the other paper, Chen and Zhou [43] developed methods
for non-homogeneous Markov processes through time scale transformation when
observation times are pre-planned with some observations missing. They have used
Maximum likelihood estimation via the EM algorithm to derive parameter estimates.
Van Den Hout and Matthews [44] formulated a continuous time three-state model
with time-dependent transition intensities to describe transitions between healthy and
unhealthy states before death. To deal with possible non-ignorable missing states, a
maximum-likelihood model is proposed for the joint distribution of both the state and
whether or not the state is observed. Yeh et al. [45], conducted a simulation study to
examine the impact of ignorable and non-ignorable intermittent missing observations
on the parameter estimates of HMM.
The other method that has been used in the literature to estimate Markov
model parameters is Bayesian inference. Assoudou et al. [46] described a Bayesian
estimation of the transition probabilities of a binary Markov chain observed from
heterogeneous individuals. Pasanisi et al. [47] focused on Monte Carlo Markov Chain
(MCMC) algorithms to perform Bayesian inference and evaluate posterior distributions
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of the transition probabilities with missing-data framework. Efthimiou et al. [48]
adopted a Bayesian framework in order to use a multi-state Markov model for the
analysis of incomplete individual patient data for a dichotomous outcome reported
over a period of time. The model accounts for patients dropping out of the study and
also for patients relapsing.
Some paper chose to review both methods to analyze the incomplete data.
Ghahramani and Jordan [49] reviewed the problem of learning from incomplete data
from two statistical perspectives: the likelihood-based and the Bayesian. They have
described a set of algorithms, derived from the likelihood-based framework, that
handle clustering, classification, and function approximation from incomplete data.
These algorithms are based on mixture modeling and make two distinct appeals to the
expectation-maximization principle, both for the estimation of mixture components
and for coping with the missing data. Deltour et al. [50] described two algorithms for
estimating Markov chain models in the case of intermittent missing data in longitudinal
studies, a stochastic EM algorithm and the Gibbs sampler, which is used for a full
Bayesian inference. Ma et al. [51] focused on analyzing data with missing at random
values within discrete-time Markov chain models. The naive method, nonlinear (NL)
method, Expectation-Maximization (EM) algorithm, and a Bayesian framework, using
an adjusted rejection algorithm to sample the posterior distribution, and estimating
the transition probabilities with a Monte Carlo algorithm are discussed in this paper.
In this chapter, we review and apply some of the hidden Markov model
parameter approximation methods to estimate breast density transition probabilities
using mammography screening data from Louisiana Cancer Prevention and Control
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Programs [4]. The results of this chapter will be used in the next section of dissertation
to evaluate the breast cancer screening policies considering breast density as an
important breast cancer risk factor.
The remainder of this chapter is as follows. In Section 3.2, we review some
of the well-known methods for estimating parameters of Markov models from an
incomplete data with ignorable missingness mechanism. In Section 3.3, we talk
about the computational analysis of a simulated data using described methods and
a description of our main dataset and the results of the parameter estimation. We
summarize and conclude in Section 3.4.

3.2 A Review of the Methodologies in the Literature
In this section, we review different methods for estimating Markov model
parameters for an incomplete longitudinal set of data, where different characteristics
of a group of patients are scheduled to be observed at equal time intervals. We
discuss methods for an ignorable mechanism of missing values. Generally, there are
three categories of methods for handling incomplete data with ignorable missingness
mechanism: deletion, imputation, and augmentation. Data deletion is the most
simple and common method. However it causes bias in parameter estimation. Data
imputation and data augmentation methods are comparatively similar methods,
however, in data imputation methods missing observations substitute with imputed
values but in data augmentation, parameter estimation is augmented by the information
gained from assuming certain probability models from observed data [52]. Data
augmentation procedures included maximum likelihood (ML) and Bayesian Inference.
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In this section, we discuss each of these methods separately. The following is the list
of notations used in these models.
• t: Time periods, t = 0, 1, · · · , T , where T denotes the number of scheduled
observations for each patient.
• Γ: Number of patients, Note that we use subscript η ∈ {1, ..., Γ} in order to
represent η th patient.
• S: Patient’s core state space, where st ∈ S represents patient’s state at time t.
Core state space will be defined based on the type of the data. For example in
analyzing breast density, we assume S = {dI , dII , dIII , dIV }, which is the set of
partially observable breast density states including almost entirely fatty tissue,
scattered fibroglandular densities, heterogeneously dense class, and extremely
dense class.
• Sη : State sequence of patient η, where Sη = sη,1 , sη,2 , ..., sη,T represents the
actual states of patient η at each time point.
• Y : Observation space, where yt ∈ Y represents the observation that the patient
gets at time t. In hidden Markov models, the state of patient is not directly
observable and it would be determine through the imperfect interpretation of
screening results.
• Yη : Observation sequence for patient η, where Yη = {yη,1 , yη,2 , ..., yη,T } represents
the observation for patient η at time t. Note that we assume the data is
not complete and some of observations are missing. In other words, we have
Yη = {Yηobs , Yηmiss }.
• m: Number of missing values between two observed values.
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• nij : Number of one-step transitions between state i and state j among all Γ
patients when the data is complete.
• ni(m)j : Number of transitions from state i to state j with m missing observations
between these two observations among all Γ patients.
• πst : Expected patient belief state at time t that represents the occupancy
distribution over core states.
• A: State transition probability matrix, where aij ∈ A represents the probability
that a patient will be in state j at time t + 1, given that s/he is in state i at
time t.
[m]

[1]

• aij : m-step transition probability from state i to state j. Note that aij = aij .
• B: Observation probability matrix, where bst (yt ) ∈ B represents the probability
of receiving observation yt given that patient is in state st at time t.
• λ: Vector of model parameters, where λ = (π, A, B).
3.2.1 Data Deletion Method
Listwise Deletion
The most common approach to handle the missing data is to exclude the cases
with missing values and analyze the remaining data. Listwise method can produce
unbiased estimates, if the sample is large enough and the missingness mechanism is
MCAR.
Pairwise Deletion
Despite the listwise method that omits the whole case if it has a missing value,
pairwise method excludes only the variable of the case with missing value. Note that
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pairwise method still uses the case when analyzing other variables with non-missing
values. This method has the best use of data and hence is more preferable compared
to listwise deletion. However, this method use different number of cases for each
analyze and it causes an overestimation or underestimation of standard errors [53].
3.2.2 Data Imputation Methods
In this section, we review some of the well-known single and multiple imputation
methods for handling missing values.
LOCF/NOCB Methods
One of the well-known single imputation methods for longitudinal data is
Last Observation Carried Forward (LOCF). This imputation method carries the last
observed non-missing value to fill in missing values at a later point. Therefore, the
response remains constant at the last observed value. A similar approach named
Next Observation Carried Backward (NOCB) works in the opposite direction by
taking the first observation after the missing value and carrying it backward. These
methods can introduce a positive or negative bias and because all the missing values
for an individual are replaced with the same numbers, the within-subject variability is
reduced [53].
Mean/Mode Substitution
Mean substitution method is another single imputation procedure where the
missing value of a variable can be replaced with the average of known values for that
variable. For categorical data, mode of the previous data can be used as substitute
value for imputation. This method’s estimation may lead to inconsistent bias, if the
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missing values are not random or the number of missing values for different variables
is not equal [53].
Regression Imputation
This approach estimates and imputes the missing data using a regression model
and other relevant variables in the dataset. Therefore, it maintains all the cases and
does not change the standard deviation or the shape of the distribution. However, in
this method other variables in the dataset are used to impute missing observations
without adding any new information. This causes an increase in sample size and
consequently a decrease in the standard error [54].
K-Nearest Neighbors Imputation Method (KNN)
The KNN algorithm stores all the training cases and when it encounters a
new input vector, it performs a prediction by considering its K closest training cases
according to a given distance metric. A well-known distance function is the Euclidean
distance which is used to identify the k nearest neighbors of each case with two inputs,
YA and YB ,
d(YA , YB ) =

sX

dϑ (YAϑ , YBϑ )2 ,

(3.4)

ϑ

where dϑ (YAϑ , YBϑ ) is the distance between the two cases on its ϑth attribute and it
can be calculated as follow,

47

dϑ (YAϑ , YBϑ ) =































1,

if Yϑ is missing in YA or YB ,

ED,

if data is continuous,

1,

if data is categorical and YAϑ 6= YBϑ ,

0,

if data is categorical and YAϑ = YBϑ ,

(3.5)

where ED is the normalized Euclidean distance and can be calculated as follow,
ED =

| YAϑ − YBϑ |
.
max(Yϑ ) − min(Yϑ )

(3.6)

Given an incomplete vector of dataset, for each missing value in Y, the KNN
imputation method finds the corresponding set of k closest training cases with observed
values in the incomplete feature to be imputed. Then, the unknown value Yϑ can be
estimated by the mean or mode of k nearest neighbors [55] and the parameter can be
estimated using the imputed complete dataset.
3.2.3 Data Augmentation Methods
In this section, we talk about methods that use maximum likelihood and Bayes
theorem as a basic for calculation of the parameters. In order to show the calculation
burden of the maximum likelihood methods that do not use data augmentation, first
we talk about a nonlinear method introduced by Yeh et al. [32] and then we talk
about expectation-maximization and Viterbi algorithms that use data augmentation
to decrease the complexity of calculations. Later in this section, we will talk about
Bayesian inference assumptions and algorithm.
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Nonlinear Maximum Likelihood Method
Nonlinear method uses all the one and multi-step transitions to compute the
parameters. For example, the (m + 1)-step transition probability from state i to state
j can be computed by summing over all possible routes,
[m+1]

aij

=

S
X
l1 =1

[m]

ail1 al1 j =

S X
S
X

[m−1]

ail1 al1 l2 al2 j

l1 =1 l2 =1

=

S X
S
X
l1 =1 l2 =1

S
X

...

ail1 al1 l2 ...alm−1 lm alm j .

lm =1

(3.7)
The log likelihood function for this equation can be expressed as,
L(λ|Y ) =

Γ X
S X
S TX
−2
X

[m+1]

ni(m)j log(aij

).

(3.8)

η=1 i=1 j=1 m=0

The MLE of the transition probabilities can be computed by solving

∆L(λ|Y )
∆λ

= 0.

This MLE function is nonlinear due to the summation inside the logarithm and should
be solved with nonlinear procedures.
Expectation-Maximization Algorithm
Expectation-Maximization(EM) algorithm is an iterative approach for a broad
range of Markov model parameter estimation. On each iteration of EM algorithm there
is an expectation step and a maximization step. In the expectation step (E-Step), a
log-likelihood function is evaluated using the current estimate for the parameters. The
second step (the M-step) of the EM algorithm is to maximize the expectation function
we computed in the E-step. To define the maximum-likelihood function, we assume
that data Y obs is observed and is generated by some distribution. We assume that a
complete dataset exists, Y = (Y obs ; Y miss ) and also assume a joint density function as,
P (Y|λ) = P (Y obs , Y miss |λ) = P (Y miss |Y obs , λ)P (Y obs |λ).

(3.9)
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In the first step, EM algorithm finds the expected value of the complete data
log-likelihood with respect to the unknown data Y miss given the observed data Y obs
and the current parameter estimates,
Q(λ, λν−1 ) = E[log P (Y obs , Y miss |λ)|Y obs , λν−1 ],

(3.10)

where λν−1 is the set of current parameters estimates that we use to evaluate the
expectation function and λ is the set of new parameters that we optimize to increase
Q . The second step (M-step) of the EM algorithm is to maximize the expectation
function we computed in the first step. That is,
λν = arg max Q(λ, λν−1 ).

(3.11)

λ

These two steps are repeated until convergence. Each iteration is guaranteed
to increase the log-likelihood and the algorithm is guaranteed to converge to a local
maximum of the likelihood function.
If the Markov model is fully observable, Equation (3.10) can be written as,
Q(λ, λν−1 ) = E[log P (Y obs , Y miss |λ)|Y obs , λν−1 ] =

S X
S
X

nνij log(aij ),

(3.12)

i=1 j=1

where nνij = ni(0)j + mνij is the ν th iterate of the expected number of transitions from
state i to state j for the whole data. Note that ni(0)j is the number of one-step
transitions and mνij is the number of multi-step transitions from state i to state j at
ν th iteration.
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In each iteration, M-step maximizes the Q function in Equation (3.12). The
(ν + 1)th iteration of the estimates of transition from state i to state j is,
âν+1
=
ij

nνij
,
nνi+

where nνi+ =

S
X

nνiι .

(3.13)

ι=1

The estimated transition probabilities aν+1
are substituted into the Q function,
ij
and the steps E and M were repeated until the Q function converges.
In order to learn the parameters of an HMM model, the EM algorithm has been
derived for finding the maximum-likelihood estimate of the parameters of a hidden
Markov model given a set of observed feature vectors. This algorithm is known as
the Baum-Welch algorithm. There are three basic problems that EM algorithm tries
to solve in each iteration and finally estimate the parameters: evaluation problem,
finding optimal state sequence problem, and optimization problem [56, 57]. Here we
will talk about each problem and the required steps for Baum-Welch algorithm.
In Evaluation problem, we compute the probability of the observation sequence
Yη = yη,1 , yη,2 , ..., yη,T for patient η given the parameters of a model, λ = (A, B, π).
One way to calculate this probability is through enumerating every possible state
sequence of length T . Consider fixed state sequence of Sη = sη,1 , sη,2 , ..., sη,T . The
probability of observation sequence of Yη for Sη state sequence is,
P (Yη |Sη , λ) =

T
Y

P (yη,t |Sη , λ) = bsη,1 (yη,1 )bsη,2 (yη,2 )...bsη,T (yη,T ).

(3.14)

t=1

In addition, the probability of state sequence Sη can be written,
P (Sη |λ) = πsη,1 asη,1 ,sη,2 asη,2 ,sη,3 ...asη,T −1 ,sη,T .

(3.15)
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The probability of Yη given the model parameters can be obtained by summing
the joint probability over all possible state sequences:
P (Yη |λ) =

X

P (Yη |Sη , λ)P (Sη |λ)

Sη

=

X

πsη,1 bsη,1 (yη,1 )asη,1 ,sη,2 bsη,2 (yη,2 )...asη,T −1 ,sη,T bsη,T (yη,T ).

(3.16)

Sη

The logic of this equation is as follow. Let’s assume patient η is in state sη,1
with probability πsη,1 and observes observation yη,1 with probability of bsη,1 (yη,1 ) at
time 1. Then, the patient makes a transition from state sη,1 to state sη,2 at time 2 with
probability asη,1 ,sη,2 and observe observation yη,2 with probability bsη,2 (yη,2 ) until s/he
gets to time T . An efficient procedure named forward-backward can be used to solve
this problem. The forward-backward algorithm computes the marginal probability of
a given state at a time point. In this procedure, the forward variable, α, is defined as
the probability of seeing the partial sequence (yη,1 , ..., yη,t ) for patient η and ending
up in state i at time t given the model parameters.
αη,t (i) =
P (Yη,1 = yη,1 , ..., Yη,t = yη,t , sη,t = i|λ),

t = 1, 2, ..., T, η = 1, 2, .., Γ.

(3.17)

where,
αη,1 (i) = πi bi (yη,1 ),
αη,t+1 (j) =

X
S



αη,t (i)ai,j bj (yη,t+1 ),

(3.18)
(3.19)

i=1

P (Yη |λ) =

S
X
i=1

αη,T (i).

(3.20)
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Similarly, we can calculate backward variable βt (i) defined as,
βη,t (i) =
P (Yη,t+1 = yη,t+1 , ...Yη,T = yη,T |sη,t = i, λ),

t = 1, 2, ..., T − 1, η = 1, 2, ..., Γ.
(3.21)

Backward variable is the probability of ending sequence (yη,t+1 , ..., yη,T ) for
patient η, given that we started at state i at time t and the model parameters. Note
that backward variable will be used in solution for optimization problem. We can
solve Equation (3.21) using two steps:
βη,T (i) = 1

βη,t (i) =

S
X

1 ≤ i ≤ S,

ai,j bj (yη,t+1 )βη,t+1 (j).

(3.22)

(3.23)

j=1

In the second problem, we try to compute the probability of a state sequence Sη = sη,1 , sη,2 , ..., sη,T for patient η given the observation sequence, Yη =
yη,1 , yη,2 , ..., yη,T and the parameters of a hidden Markov model, λ = (π, A, B) to find
the optimal state sequence. The optimality criteria that has been used for this section
is expected to maximize the expected number of correct individual states. For this
purpose we define,
γη,t (i) = P (sη,t = i|Yη , λ) =

P (sη,t = i, Yη |λ)
αη,t (i)βη,t (i)
= PS
,
P (Yη |λ)
j=1 αη,T (j)

(3.24)

where γη,t (i) is the probability that patient η is in state i at time t, given the observation
sequence of Yη and the model parameters of λ. Using γt (i), we can find the most
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likely sequence of states for an observation sequence,
sη,t = arg max[γη,t (i)].
1≤i≤S

(3.25)

In optimization problem, we implement an iterative procedure to estimate the
parameters of the model. In this procedure, HMM parameters will be updated and
improved iteratively. For this purpose, first we define ξη,t (i, j) as the probability of
patient η being in state i at time t and in state j at time t + 1, given the parameters
of the model and observation sequence.
ξη,t (i, j) = P (sη,t = i, sη,t+1 = j|Yη , λ) =
=

P (sη,t = i, sη,t+1 = j, Yη |λ)
P (Yη |λ)
αη,t (i)aij bj (yη,t+1 )βη,t+1 (j)
.
PS
i=1 αη,T (i)

(3.26)

Note that based on our definition for γη,t (i) as the probability of patient η
being in state i at time t, given the observation sequence and the model, we can relate
γη,t (i) to ξη,t (i, j) by summing over j, giving,
γη,t (i) =

S
X

ξη,t (i, j).

(3.27)

j=1

In addition, summing γη,t (i) over t, we get the expected number of transitions
from state i. Similarly, summation of ξη,t (i, j) over t can be interpreted as the expected
number of transitions from state i to state j.
Using the above formulas, we can estimate HMM parameters in each iteration.
πiν : Expected probability of being in state i at time 1
ν
η=1 γη,1 (i)
,
PS
ν
η=1
i=1 γη,1 (i)

PΓ

= PΓ

(3.28)
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aνij :

bi (j)ν :

Expected number of transitions from state i to j
Expected number of transitions from state i
PΓ PT −1 ν
t=1 ξη,t (i, j)
,
= Pη=1
PT −1 ν
Γ
η=1
t=1 γη,t (i)
Expected number of times in state i and observing j
Expected number of times in state i
PΓ PT
ν
t=1 γη,t (i)δ(yη,t = j)
,
= Pη=1
P
Γ
T
ν
η=1
t=1 γη,t (i)δ(yη,t 6= .)

(3.29)

(3.30)

where δ(yη,t = j) is the index function that equals 1 if the η th patient at time t is
observed to be in state j, and zero otherwise.
Viterbi Algorithm
The Viterbi algorithm estimates the state sequence of a discrete-time finitestate Markov process by recursively taking the most probable path that could lead to
each cell. Based on Rabiner [57] to implement this algorithm first we define,
ζη,t (j) = s

max

η,1 ,sη,2 ,sη,t−1

P (yη,1 , yη,2 , ..., yη,t , sη,1 , sη,2 , ..., sη,t−1 , sη,t = j|λ).

(3.31)

Note that ζη,t represents the most probable path by taking the maximum
over all possible previous state sequences given that we had already computed the
probability of being in every state at time t − 1. For a given state sj at time t and for
patient η, the value ζη,t (j) can also be computed as,
S

ζη,t (j) = max ζη,t−1 (i)aij bj (yη,t ).
i=1

(3.32)

The actual state sequence is retrieved by tracking the transitions that maximize
the ζη,t (j) scores for each patient, time point t and state j using ψη,t (j).
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Modified Viterbi algorithm can be used when the dataset contains some missing
values [58]. The steps required for this algorithm is
1. Detect the most probable path at each time over all possible previous state
sequences.
If t = 1,
ζη,1 (i) =







πi ,

yη,1 is missing,






πi bi (yη,1 ),

otherwise,

(3.33)

ψη,1 (i) = 0.
If t = 2, · · · , T ,

ζη,t (j) =







max1≤j≤S [ζη,t−1 (i)aij ],

yη,1 is missing,






max1≤j≤S [ζη,t−1 (i)aij bj (yη,t )],

otherwise,

(3.34)

ψη,t (j) = arg max[ζη,t−1 (i)aij ].
1≤i≤S

2. Update the terminal state,
sT = arg max[ζη,T (i)].

(3.35)

sη,t = ψη,t+1 (sη,t+1 ).

(3.36)

1≤i≤S

3. State sequence backtracking

In each iteration, the algorithm generates a new set of parameters based on
the most probable state sequence and previous estimation of parameters. The Viterbi
algorithm is expensive, both in terms of memory and compute time [59].
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Bayesian Inference (MCMC)
In this section, we review Gibbs sampler method derived from Vidotto et al.
[60] and investigate the performance of mixture hidden models for missing categorical
longitudinal data. This model is implemented using Bayesian inference method which
requires defining the prior distribution of the model parameters in order to obtain the
posterior distribution of the model’s unknown parameters given the observed data
(Y obs ). In this method, the V sets of imputations are obtained from the posterior
predictive distribution of the missing data. To implement this method, first, we
sample parameter values, λν (ν = 1, ..., V ), from P (λ|Y obs ) and then the imputations
are drawn from P (Y mis |λν ).
To estimate the parameters of hidden Markov model, a Multinomial distribution
is defined for each of the categorical variables as follow,
• (sη,1 ) ∝ Multinomial(π), where π = (π1 , ..., πS ) is the initial state probabilities
vector.
• (sη,t+1 |sη,t = i) ∝ Multinomial(ai ), ∀t , where ai is the transition probability
vector starting from state i.
• (yη,t |sη,t = i) ∝ Multinomial(bi ), where bi = (bi (1), ..., bi (Y )) is the observation
probability vector given we are in state i.
The core of Bayesian inference is to combine two different likelihood and prior
distributions into one posterior distribution to estimate the parameters. Since the
variables are categorical and we have multinomial distribution as likelihood distribution,
if we choose a conjugate prior distribution, instead of multiplying the likelihood with
the prior distribution, the posterior distribution can be updated easily using the
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prior parameters. In view of the fact that Dirichlet distribution is the conjugate of
multinomial distribution, we define the prior distribution of parameters as follow,
• π ∼ Dirichlet(ω) with ω = (ω1 , ..., ωS ),

ωs > 0,

• ai ∼ Dirichlet(θ), with θ = (θ1 , ..., θS ),

θs > 0,

• bi ∼ Dirichlet(ϕi ), with ϕi = (ϕi (1), ..., ϕi (Y )),

∀s .
∀s .
ϕi > 0,

∀i .

To choose the model parameters for each these Dirichlet distribution, if we
have no previous knowledge about the imputation of model parameters, a symmetric
Dirichlet priors can be chosen (Dirichlet(c1 , c2 , ..., cs ) where c1 = c2 = ... = cs ).
The Gibbs sampler has been used in this section for model estimation and
imputation. The algorithm steps are as follow,
1. Sample hidden states for each patient η = 1, ..., Γ and for all time points
t = 1, ..., T from a conditional categorical distribution defined by the following
probabilities.
P (sνη,t |λν−1 , yη,t ).
At t = 1, for all patients η = 1, ..., Γ, and for all states j = 1, ..., S,
π ν−1 bj (yη,1 )ν−1
P (sνη,1 = j|λν−1 , yη,1 ) = P j ν−1
.
bc (yη,1 )ν−1
c πc

(3.37)

For t = 2, ..., T and for patients η = 1, ..., Γ we have,
P (sνη,t

= j|λ

ν−1

, yη,t ) =

P

i

ν−1
P (sνη,t−1 = i|λν−1 , yη,t−1 )aν−1
ij bj (yη,t )
.
P
ν
ν−1 , y
ν−1
η,t−1 )bc (yη,t )
c P (sη,t = c|λ

(3.38)
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2. Update each parameter values as follow,
For initial state probabilities (t = 1) ∀η ,
π ν |sνη,1 ∼
Dirichlet(ω1 +

X

Iη,1 (sνη,1 = 1), ..., ωS +

η

X

Iη,1 (sνη,1 = S)),

(3.39)

η

where Iη,t (sνη,t = s) = 1 if for patient η, sνη,t = s and 0 otherwise.
For transition probabilities and for i = 1, ..., S and ∀η,t≥1 ,
aνi |sνη,t , sνη,t+1 ∼
Dirichlet(θ1 +

Iη,t+1 (sνη,t+1 = 1), ..., θS +

X
η,sνη,t =i

Iη,t+1 (sνη,t+1 = S)).

X
η,sνη,t =i

(3.40)
For the emission probabilities and for j = 1, ..., S and ∀η,t ,
bνj |sνη,t , Y obs ∼
Dirichlet(ϕj (1) +

X

Iη,t (yη,t = 1), ..., ϕj (Y ) +

η,sνη,t =j

X

Iη,t (yη,t = Y ),

η,sνη,t =j

(3.41)
where Iη,t (yη,t ) = 1 if yη,t = y and yη,t ∈ Y obs and 0 otherwise.

3.3 Computational Analysis
In this section, first, we conduct a simulation to study the accuracy of the
Markov model parameter estimates obtained from Baum-Welch and Bayesian Inference
algorithms. The simulated data will have the same number of states, patients, and
missing mechanism as our main dataset. In addition, we present the estimated Markov
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parameters and the bootstrapping standard errors for breast density longitudinal
dataset in Section 3.3.2.
3.3.1 Monte Carlo Simulation
In order to understand the impact of missing values and their uncertainty in
estimating model parameters, we construct a Mont Carlo simulation. The objective
of this simulation is to approximate the sampling distribution of an estimator by
generating large number of random independent datasets from a known values of the
parameters and computing the estimator for each dataset using different algorithms.
The sample mean of the estimates over all datasets is an estimate of the mean of the
sampling distribution of the estimator and the standard deviation of the estimates
over all datasets is an estimate of the standard deviation of the sampling distribution.
The following are the basics of this simulation model,
• Generate D datasets from true statistical parameters with true value of λ.
• For each dataset, estimate λ using each of the algorithms.
• Obtain bias, mean square error, and standard error for λ.
Let λ̂ be the estimator of true value of parameters and λ̂∫ be the estimate
obtained from the ∫ th dataset, where ∫ = 1, ..., D. We would want to calculate an
unbiased estimator for the parameters. Thus, we would hope that the mean of the
sampling distribution is close to the true value of λ with only small bias. To assess
this difference of values, we calculate the Monte Carlo bias for estimator λ̂ from the
sampling distribution as follow,
Bias =

D
1 X
λ̂∫ − λ.
D ∫ =1

(3.42)
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To compare the precision of two estimators based on the D estimates of each,
we could compare the Monte Carlo mean square error (MSE) for each estimator. The
estimated MSE based on the D estimates λ̂∫ is defined as,
MSE =
where λ̄ =

1
D

PD

∫ =1

D
D
1 X
1 X
(λ̂∫ − λ)2 =
(λ̂∫ − λ̄)2 + (λ̄ − λ)2 ,
D ∫ =1
D ∫ =1

(3.43)

λ̂∫ . Note that second part of Equation (3.43) includes square values

of the bias and standard error of estimator based on D observations.
For our purpose, we generated simulated datasets with the same number of
states, patients, missing mechanism, and missing value percentage as our main dataset
which will be discussed in Section 3.3.2. The simulation was repeated 1000 runs
for each method under each scenario. We estimated the transition parameters and
compared the estimates to the true parameter values in terms of bias, standard errors,
and mean square errors (MSE). Based on simulation results, when the model is fully
observable both algorithms estimate parameters with high accuracy. However, for
a hidden state sequence of observations, Baum-Welch algorithm has lower bias and
lower required calculation time.
3.3.2 Main Data Description and Bootstrapping
This section describes a longitudinal dataset that is used to quantify the
dynamics of breast density which will be used in our last chapter for evaluation of
breast screening policies considering patients’ breast density. This longitudinal data
has been gathered from 436 patients since 2016 at Louisiana Cancer Prevention and
Control Center [4]. The records of patients give us information about the patient’s date
of birth, date of screening, BI-RADS health and density states, future recommendation,
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and radiologist name. This dataset contains missing values which comes from the
missed scheduled visits of patients for evaluation of their health and breast density
status. We assume the missingness mechanism in this dataset is ignorable since the
probability of a patient shows up for breast screening mostly depends on their previous
screening results rather than current observation. This comes from the fact that the
symptomatic breast cancer usually happens at the very advanced stage of a cancer,
which means that patients who show up for screening are mostly because of previous
suspicious results or to follow-up the screening policy recommendation. Furthermore,
we divided observations based on the age of patients into two groups (40 − 55/55+)
in order to consider the age and menopause effect on breast density dynamics in our
analysis. The summary counts for observed breast density status and transitions for
each group are shown in Table 3.1.
Table 3.1 Transition counts between different states in breast density dataset

one-step

two-step

1
2
3
4

dI
dII
dIII
dIV
dI
dII
dIII
dIV

dI 1
41
11
0
0
8
5
0
0

40+
dII 2
8
200
29
0
1
52
12
0

dIII
0
10
126
3
0
3
33
2

3

dIV
0
0
2
2
0
0
0
2

4

dI
11
4
0
0
4
2
0
0

40-55
dII
5
61
13
0
0
16
3
0

dIII
0
4
61
1
0
1
17
1

dIV
0
0
2
1
0
0
0
1

dI
26
7
0
0
5
1
0
0

55+
dII
2
136
15
0
1
27
8
0

dIII
0
6
60
1
0
2
15
1

dIV
0
0
0
1
0
0
0
1

Almost entirely fatty
Scattered fibroglandular densities
Heterogeneously dens
Extremely dense

Due to small sample size for each age group and in order to assess the uncertainty
of estimation, we also conduct a bootstrap that can be described as follow; we generate
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a bootstrap set, by randomly sampling nB patients with replacement from the main
dataset. Based on Efron’s recommended bootstrap ([61]), the sample size is assumed
to be the same as the original sample size and the sampling distribution is uniform,
which means that each of the patients in dataset has the same probability of being
selected. We repeat this sampling τ times to generate τ bootstrap sets, B1 , B2 ,. . . ,
Bτ . Finally, we construct a sampling distribution with these τ bootstrap statistics.
The initial values for the baseline distribution with starting ages 40 and 55
were chosen based on population distribution in Mandelblatt et al. [62] as:
"

π

(40)

π

(55)

#

= 0.046 0.338 0.472 0.144
"

#

= 0.098 0.471 0.373 0.058

We also chose the initial information matrix arbitrarily as,


B=

0.85




0.07




0.02






0.12 0.02 0.01

0.75 0.15
0.1

0.8

0.01 0.04 0.15




0.03



0.08





0.8

For the initial transition probabilities, we used the normalized one-step observation counts in each dataset. Table 3.2 shows the parameter estimator values,
standard error and bootstrapping 95% confidence interval. Based on the estimates for
yearly transitions, the successive observations are more likely to recur, which means
that the amount of fibroglandular tissue in a patient’s breast is most likely to stay
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similar as the previous year for all four classes. However, the results show a higher
probability of decline and lower probability of increased breast density per year as
the patient’s age increases. In addition, higher breast tissue density shows a higher
decline each year. For example there is 28.6% probability of transitioning from state
4 to state 3 compared to 12.9% and 3.4% probability of transitioning from state 3
to state 2 and from state 2 to state 1, respectively. Based on the results for all age
groups, the probability of transitioning between two nonconsecutive states is almost
impossible. This means that if the state of patient’s breast density is 3, the probability
of changing state to 1 in one year is zero.
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Table 3.2 HMM estimates, standard errors, and 95% confidence intervals for breast
density dataset
Age Groups Transition from dI
0.947 (0.030)
dI
(0.874,0.995)
40+
0.034 (0.012)
dII
(0.012,0.06)

Transition to
dII
dIII
0.053 (0.030) 0 (0)
(0.005,0.126) (0,0)

dIV
0 (0)
(0,0)

0.960 (0.013)
(0.934,0.983)

0.006 (0.004)
(0.001,0.016)

0 (0)
(0,0)

dIII

0 (0)
(0,0)

0.129 (0.026)
(0.08,0.179)

0.869 (0.026)
(0.819,0.918)

0.002 (0.001)
(0,0.005)

dIV

0 (0)
(0,0)

0 (0)
(0,0)

0.286 (0.109)
(0.093,0.518)

0.714 (0.109)
(0.482,0.907)

dI

0.900 (0.075)
(0.722,0.999)

0.100 (0.075)
(0.001,0.278)

0 (0)
(0,0)

0 (0)
(0,0)

dII

0.032 (0.021)
(0.001,0.081)

0.960 (0.021)
(0.911,0.993)

0.009 (0.007)
(0,0.027)

0 (0)
(0,0)

dIII

0 (0)
(0,0)

0.107 (0.033)
(0.047,0.174)

0.885 (0.034)
(0.817,0.946)

0.008 (0.006)
(0.002,0.024)

dIV

0 (0)
(0,0)

0 (0)
(0,0)

0.232 (0.102)
(0.068,0.468)

0.768 (0.102)
(0.532,0.932)

dI

0.979 (0.015)
(0.942,0.999)

0.021 (0.015 ) 0 (0)
(0.001,0.058) (0,0)

0 (0)
(0,0)

dII

0.026 (0.011)
(0.008,0.052)

0.962 (0.012)
(0.938,0.984)

0.012 (0.005)
(0.003,0.024)

0 (0)
(0,0)

dIII

0 (0)
(0,0)

0.139 (0.036)
(0.079,0.221)

0.861 (0.036)
(0.779,0.921)

0 (0)
(0,0)

dIV

0 (0)
(0,0)

0 (0)
(0,0)

0.338 (0.1)
(0.162,0.436)

0.662 (0.1)
(0.564,0.838)

40-55

55 +
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3.4 Conclusion
In this section, we reviewed several methods to estimate Markov model
parameters using a set of data with intermittent missing values. We discussed three
categories of methods for datasets with ignorable missingness mechanism including
deletion, imputation, and augmentation. Moreover, we executed these methods on
several simulated data to measure the bias of the results from each algorithm. Based
on the simulation results, algorithms tend to have a very small bias if the Markov
model is fully observable. However, the uncertainty in the accuracy of the observations
adds bias to these estimates. Finally we implemented Baum-Welch algorithm on a set
of incomplete dataset consist of hidden observations for breast density of a group of
patients at Louisiana Cancer Prevention and Control center. Due to the small size of
dataset, we used the bootstrapping method to reduce the bias of estimations. Based
on our results, estimated breast density transition matrices specify a relatively high
probability that successive observations recur. This implies that future outcome has
a high dependency on the current outcome. The results of breast density transition
probability estimations will be used as the basic parameters in section 4 to evaluate
the efficacy of supplemental screening tests for high breast density patients.
One of the limitation of this study is the small number of longitudinal
observations for each patient. One possible direction for future study could be
defined as implementing these methods on a larger dataset with more number of
observations for each patient.

CHAPTER 4
INVESTIGATING THE EFFECTIVENESS OF BREAST
DENSITY NOTIFICATION LAW CONSIDERING
RADIOLOGISTS BIAS
4.1 Introduction
Breast density is defined as the prevalence of fibroglandular tissue in the breast.
The Breast Imaging Reporting and Data System (BI-RADS) classification system
classifies breast tissue density into four categories: almost entirely fatty which includes
less than 25 percent glandular tissue (type 1), scattered fibroglandular densities
which includes approximately 25-50 percent glandular tissue (type 2), heterogeneously
dense class which includes approximately 51-75 percent glandular tissue (type 3), and
extremely dense class which includes more than 75 percent glandular tissue (type
4) [63]. Higher breast density can significantly reduce the mass detection rate since
the normal tissues in dense breasts appear as bright areas in mammography. Breast
density is also associated with increased risk of breast cancer [5]. It is well-established
that tumors in dense breasts may progress more rapidly than those in fatty breasts
[5]. In addition, due to the lower sensitivity of screening mammography in women
with dense breasts, the cancer is more likely to remain undetected. Keefer [64] showed
that the relative risk associated with breast density is substantially higher than other
relative risks such as a family history of breast cancer, and menstrual and reproductive
66
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risk factors. The reported odds ratio for developing breast cancer for the most dense
compared with the least dense breast tissue categories ranges from 1.46 [65] to 6.0 [66].
Breast density is a dynamic risk factor and typically decreases as a patient
becomes older [67, 68, 69]. Younger women (especially those in premenopausal status)
are more likely to have dense breasts [70]. According to Mandelblatt et al. [62], 58.8%
of women aged 40-49 have highly dense breasts, while this percentage decreases to
42.7% and 31.1% for women aged 50-64 and 65-74, respectively.
Breast density notification laws have been enacted in 38 states in the U.S. (as
of August 2020) to mitigate the increased breast cancer risk in women with high breast
density which is partially caused by the masking effect of dense breast in screening
mammography. These laws generally require physicians to notify patients with high
breast density of their increased risk of breast cancer compared to low breast density
women [63]. Moreover, in some states, the breast density notification law requires
physicians to inform women with high breast density that adjunctive screening tests
such as breast ultrasonography (US) and magnetic resonance imaging (MRI) may
benefit them. Breast ultrasound uses high frequency sound waves to make an image of
breast tissues and as a result has higher sensitivity than mammography in women with
dense breasts. MRI uses intravenous contrast solution injection in order to produce
3-dimensional images of breast tissue.
Since the emergence of breast density notification laws, there have been
a lot of controversy on its potential unintended consequences as well as quality
of its implementation. It is believed that supplemental screening may result in
an increased number of unnecessary biopsies and patients’ overdiagnosis (that is,
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detection of a cancer that would not have become clinically apparent over the patient’s
lifetime if left undetected). In addition, inter and intra-variabilities in breast density
classification by radiologists raised some concerns since it results in patients’ breast
density misclassification (e.g., classification of a patient to a breast density category
different from her true BI-RADS breast density class) [71]. According to Bahl et al.
[72], the percentage of mammogram images reported as dense decreased after the
enactment of breast density notification law. This reduction happens as radiologists
may downgrade their assessment of density to avoid reporting requirements. On
the other hand, there have been controversies that radiologists may upgrade their
assessments so that supplemental screening can be ordered and their liability is
minimized [72].
Currently, there is not a consensus among different health agencies in the U.S.
regarding the necessity of supplemental screening in early breast cancer detection for
women with high breast density. The American College of Radiology (ACR) advocates
the use of ultrasound as an adjunctive screening test in women with dense breast tissues
[73]. However, according to the ACS report, there is not enough evidence to make a
recommendation for or against supplemental screening in addition to mammograms for
women with dense breasts [74]. The U.S. Preventive Services Task Force (USPSTF)
and the American College of Physicians (ACP) state that the current evidence is not
sufficient to support recommendation of supplemental screenings [75, 76].
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4.2 Relevant literature
In breast cancer related studies, Markov models have been previously used to
evaluate/optimize breast cancer screening and treatment strategies. Nohdurft et al.
[77] formulated a Markov decision process (MDP) model to derive optimal surgery
decisions for women with breast cancer. Chhatwal et al. [78] developed a finitehorizon discrete-time MDP to provide patient-specific recommendations for breast
biopsy based on the patient’s mammographic features. Alagoz et al. [79] formulated
a finite-horizon discrete-time MDP to optimize the post-mammography diagnostic
decisions (choosing between biopsy or short-interval follow up mammogram) based on
mammogram test findings. Ayvaci et al. [80] developed an MDP model to optimize
the risk-sensitive diagnostic decisions after a mammography exam. In their study, the
radiologist can select from biopsy, short-term follow-up, and routine mammography
while considering the patient’s preferences to maximize the quality-adjusted survival
duration. In another study, Ayvaci et al. [81] investigated the impact of budgetary
restrictions on breast biopsy decisions by developing a finite-horizon discrete-time
constrained MDP. Çağlayan et al. [82] developed a Markov model to capture the
breast cancer progression in women with certain risk factors such as gene mutations
and family history of breast and ovarian cancer. They identified the optimal and most
cost-effective population screening strategies.
As mammography is not perfect and may not reflect the true health status of a
patient, some studies used partially observable Markov models in assessing/optimizing
breast cancer screening policies. Maillart et al. [15] formulated a partially observable
Markov chain (POMC) model to compare different policies in terms of lifetime breast
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cancer mortality risk and the expected number of mammograms a woman should undergo under each screening policy. Ayer et al. [83] formulated a finite-horizon, partially
observable Markov decision process (POMDP) to determine optimal personalized
mammography screening policies based on patients’ different risk characteristics. In another study, Ayer et al. [23] developed a POMDP framework to analyze the importance
of heterogeneity in women’s adherence to mammography screening policies. Madadi
et al. [22] developed a discrete-time POMC model to evaluate mammography screening
policies in terms of the expected QALYs and lifetime breast cancer mortality risk
while incorporating the uncertainty in women’s adherence behaviors. Molani et al. [3]
developed two POMCs to quantify the age and stage-specific overdiagnosis risks while
considering the uncertainty in a patient’s adherence behavior. Cevik et al. [84] proposed
a POMDP model to maximize the total expected QALYs of a patient when there is a
constraint on the number of mammograms the patient can undergo. Sandikci et al. [85]
formulated a POMDP model to determine the optimal breast cancer screening policies
considering patients’ breast density as risk factor. Otten et al. [86] formulated a finite
horizon discrete-time POMDP to optimize and personalize breast cancer follow-up.
In this chapter, we develop a POMC model to investigate the impact of the
radiologist bias on patients’ health outcomes under the breast density notification law.
The patients’ outcomes include probability of detecting breast cancer in early and
advanced cancer states and the expected number of supplemental screening a patient
undergoes in her lifetime. To the best of our knowledge, Sandikci et al. [85] work, is
the only study that investigate breast density notification law and explicitly considers
breast density as a risk factor. Our study, however, is different from Sandikci et al.’s
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work from several aspects: 1) We consider the conditional probability of detecting
breast cancer in early and advanced states given the patient develops cancer in her
lifetime as the main patient’s outcome. This is the first study in the literature to
consider these probabilities as patients’ outcomes. Note that the main purpose of
cancer screening is to detect the cancer in early states where it is more likely to be
cured. 2) We investigate the impact of radiologists’ bias in density classification of
mammogram images on patients’ outcomes. This is done by modeling breast density
as a partially observable variable. In Sandikci et al.’s work, however, breast density is
assumed to be fully observable (i.e., radiologist’s evaluation of breast density perfectly
correlates with the patient’s actual density). 3) In this study, we use sequential
mammography screening data of 436 patients from Louisiana Cancer Prevention and
Control Programs [4] to estimate the dynamics of breast density to better capture the
breast cancer risk dynamic caused by change in breast density.
The remainder of this chapter is as follows. In Section 4.3, we present our
proposed POMC model and calculate the probability of detecting cancer in early and
advanced states and the expected number of screening tests a patient undergoes in her
lifetime under a screening strategy. Section 4.4 presents parameter estimations and
model validation. Numerical results and sensitivity analyses are presented in Section
4.5. We summarize and conclude in Section 4.6.

4.3 Model formulation
A discrete-time finite-horizon partially observable Markov chain (POMC) is
developed to model the breast cancer natural history and breast density dynamics.
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A POMC is used as the imperfect nature of mammography tests (i.e., possibility of
receiving false positives and false negatives) as well as the possibility of breast density
misclassification by radiologists prevent the patient’s true state to be fully observable
to the decision maker.
The patients’ outcome measures include the lifetime conditional probability of
detecting cancer in early and advanced states. That is, we focus on the population of
patients who would eventually develop breast cancer at some point in their lifetimes
and their cancer eventually becomes symptomatic if not detected through screening
tests. The latter assumption is made to rule out the over-diagnosed cases as for these
cases, detection of cancer is not favourable. Note that early detection of cancers which
will eventually become problematic is the main incentive of screening programs.
Obviously, the more aggressive a screening strategy is (more frequent and
multiple screening modalities), the higher is the chance of detecting the cancer in early
state when it is more likely to be treated. However, there are disutilities associated
with screening tests which adversely impacts patient quality of life. Therefore,
there is a trade-off between detecting a cancer in early state and the discomfort
of undergoing aggressive frequent screening. As such, we consider the expected
number of supplemental screening tests a patient would undergo in her lifetime as
another patients’ outcome to investigate the trade-ff.
We estimate the probability of eventually detecting breast cancer in early and
advanced state in Section 4.3.1 and the expected number of supplemental screening
tests a patient may undergo in her lifetime in Section 4.3.2. The following is the list
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of notation used in the proposed model. Note that vectors and matrices notations are
in bold.
• t: Time periods, t = 0, 1, 2 · · · , T .
• s: Patient’s core state; Specifically, s = (h, d) ∈ Ω = H

D represents the

patient’s underlying state where h ∈ H and d ∈ D denote the patient’s core
health and breast density states, respectively. The health state set H includes
three partially observable states of cancer free (state 0), early breast cancer
(state 1), and advanced breast cancer (state 2) and one fully observable state of
death due to breast cancer of other causes (state 3). Specifically, we refer to the
partially and fully observable health state sets as H1 , and H2 , respectively, i.e.,
H = H1 ∪ H2 . We denote the subsets of patient’s core states for which h ∈ H1
and h ∈ H2 by Ω1 and Ω2 , respectively. Moreover, set D includes four BI-RADS
density classes as discussed in Section 4.1, i.e., D = {1, 2, 3, 4}.
• βt : A vector of length |Ω1 | representing the patient’s belief state at the beginning
of period t. Specifically, βt (s) denotes the probability that the patient is in
partially observable state s = (h, d), h ∈ H1 at the beginning of period t.
• Pt : Underlying transition probability matrix capturing the natural history of
breast cancer and breast density dynamics. That is, Pt (s0 |s) represents the
probability that a patient will be in state s0 = (h0 , d0 ) at time t + 1, given that
she is in state s = (h, d) at time t.
• at : Prescribed action at time t, where possible actions include wait and mammography, denoted by W and M , respectively. A patient classified as high density
may undergo a supplemental screening following a negative mammogram, for
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which case the action is denoted by B. Let A denote set of all possible actions;
we have at ∈ A = {W, M, B}
• ot : Observation received at time t which includes both breast density classification
by the radiologist and screening result. Specifically, ot = (θ, δ), where θ ∈ Θ = D
and δ ∈ ∆a respectively denote the assigned breast density class and screening
result. For notation brevity, we define density observation subsets Θ = {1, 2}
and Θ̄ = {3, 4}. Clearly, we have Θ = Θ ∪ Θ̄. Observations are received only if
the prescribed action is to undergo a mammogram. Specifically, when patient
undergoes only a mammography, the possible test results are negative and positive
mammogram denoted by M − and M + , respectively. That is, ∆M = {M − , M + }.
When a mammogram is accompanied with a supplemental test (i.e., at = B),
possible observations are M − &S − and M − &S + which respectively represent a
negative and a positive supplemental test followed by a negative mammogram,
i.e., ∆B = {M − &S − , M − &S + }. If the action is wait, no observations will be
received.
M
• QM
t : Breast density information matrix, where Qt (θ|d) denotes the probability

of a patient with true density d be classified in density class θ upon action
at = M .
• Kta : Health information matrix, where Kta (δ|s) represents the probability of
observation δ ∈ ∆a when action a ∈ {M, B} is taken and the patient’s true
state is s = (h, d) at time t. Note that health observation probability matrix for
the case that the action is a mammogram, is a function of breast density due to
the masking effect of high breast density on mammogram sensitivity.
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• ηt : A vector of length |Ω1 | representing the probabilities of a patient showing
symptoms in period t. Specifically, ηt (s) is the probability of showing symptoms
in state s at time t.
The one-period sample path for the breast cancer detection process under the
notification law is presented in Figure 4.1. At each period, depending on the prescribed
action and possible subsequent observations, patient takes a different path. We assume
that after receiving a positive screening result (either a mammogram or a supplemental
test), the patient undergoes a biopsy test. Biopsy is assumed to be perfect as its true
positives rate is very close to 1 [87]. According to the U.S. Department of Health &
Human Services report, surgical biopsy could be considered a test without measurement
error [88]. We assume that probability of both developing cancer and showing
symptoms in one period (one year) is zero. That is, cancers can only show symptoms in
a period when the patient is in a cancer state at the beginning of that period. Moreover,
we assume that breast cancer cannot spontaneously (without treatment) regress [89].
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Figure 4.1: One-period sample path of the breast cancer detection process when
supplemental screening is administered. Note that under action wait, symptoms can
happen when the patient is in a cancer state
At each period, the patient’s belief state is updated based on the action and
possible observations received. Under action at , observation ot and assuming that the
patient belief at the beginning of period t is βt , Equation (4.1) calculates the patient’s
updated belief state (ν) at time t + 1:
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ν[βt , at , ot ](z) =
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1− s0 ∈Ω Pt (s0 |s)
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P


β (s)Pt (z|s)

s∈Ω1 t


,
P
P
s∈Ω1

βt (s) 1−

s0 ∈Ω2

Pt (s0 |s)

if at = M, ot = (θ, M − ), θ ∈ Θ,
if at = B, ot = (θ, M − &S − ), θ ∈ Θ̄,
if s = (0, d), at = M, ot = (θ, δ),

(4.1)

δ ∈ {M + , M − &S + },
if at = W.

The first and second case in Equation (4.1) represents the case when the patient
undergoes a prescribed mammogram, receives a negative result and is classified into
the low and high density class by the radiologist, respectively. In the latter case,
the patient undergoes a supplemental screening test and receives a negative result.
We use Bayes rule to update the patient’s belief state in these two cases. In the
second case where the patient undergoes both mammography and supplemental tests,
the joint information from both tests is used to update the patient’s belief state.
The third case represents a false positive and consists two different situations: 1) a
false positive mammogram result, and 2) a negative mammogram followed by a false
positive supplemental test. In these cases, the patient’s belief is updated by accounting
for possible cancer development from the cancer-free state (s = (0, d)). The fourth
case represent the situation where the action is wait. In this case, no observation is
received and the dynamics of breast cancer natural history and breast density is used
to update the patient’s belief state. The term 1 −

P

s=(h0 ,d0 ),h0 ∈H2

Pt (s0 |s) in the third

and fourth cases represents the probability that a patient in state s survives period t.
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4.3.1 Probability of detecting cancer in early and advanced states
Let Eta (βt ) and Aat (βt ) denote the probability of eventually detecting a cancer
in early and advanced cancer states when the patient belief state in period t is βt
and action a is taken, respectively. Note that we only consider the cancer population
for which the cancer will eventually show symptom. That is, we exclude the overdiagnosed cases whose cancer may never show symptoms or cause any problem in the
patient’s lifetime. Equations (4.2) and (4.3) calculate these probabilities for the case
when the prescribed action in epoch t is wait:

EtW (βt )



X

=

βt (s) 0 +

a
ρ0t (s)Et+1



ν[βt , W, ·] + 1 −


ρ0t (s)



·0

s=(0,d)



X

+



βt (s) ηt (s) + (1 − ηt (s))

a
ρ1t (s)Et+1



ν[βt , W, ·] + 1 −


ρ1t (s)



·0

s=(1,d)

X

+

βt (s) · 0,

(4.2)

s=(2,d)

where

ρ0t (s)

=

P

z=(h0 ,d0 ):h0 ∈{0,1}

1−

P

s0 ∈Ω2

Pt (z|s)

Pt (s0 |s)

is the probability of remaining in the healthy

states or transitioning to early cancer states in period t given that the patient is
healthy (i.e., s = (0, d)) at the beginning of period t and survives the current period.
Additionally,

ρ1t (s)

=

P
P (z|s)
z=(1,d0 ) t
P
0

1−

s0 ∈Ω2

Pt (s |s)

is the probability of remaining in early cancer

state (i.e., s = (1, d)) in period t given that the patient survives the current period.
The logic of Equation (4.2) is as follows: If the patient is in a healthy state
at time t, the probability of cancer detection in the current period is zero. The
future probability of eventually detecting cancer in early state is conditioned on
patient’s surviving the current period. In addition, the patient should stay healthy
or if developed cancer, she has to be in an early cancer state in order to be possible to
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detect the cancer in an early stage as we assume that cancers cannot spontaneously
regress. The probability of such event is ρ0t (s) and in such a case, the future probability




a
of cancer detection in early state is Et+1
ν[βt , W, ·] . Note that ν[βt , W, ·] is the patient

updated belief under action wait and is calculated using Equation (4.1). If the patient
transitions to an advanced cancer state (with probability 1 − ρ0t (s)), the probability
that the cancer is eventually be detected in an early state is zero. If the patient is
in an early cancer state at the beginning of period t, the cancer may show symptoms
with probability ηt (s). In this case, the follow-up tests will reveal the cancer and
the patient leaves the model. If the cancer remains undetected in the current period
(which happens with probability 1 − ηt (s), s = (1, d)) and the patient remains in early
cancer state (which happens with probability ρ1t (s)), the cancer might be eventually




a
detected in an early state with probability Et+1
ν[βt , W, ·] . If the patient is in an

advanced cancer state at the beginning of period t, the cancer can never be detected
in an early state since we assume that no cancer regression can occur.

AW
t (βt )

=

X



βt (s) 0 +

ρ0t (s)Aat+1



ν[βt , W, ·] + 1 −


ρ0t (s)



·1

s=(0,d)

+

X







βt (s) 0 + (1 − ηt (s)) ρ1t (s)Aat+1 ν[βt , W, ·] + 1 − ρ1t (s) · 1




s=(1,d)

+

X

βt (s) · 1.

(4.3)

s=(2,d)

The logic of Equation (4.3) is as follows: If the patient is in a healthy state
at the beginning of period t, the immediate probability of detecting cancer in an
advanced state is zero. If the patient stays in a healthy or transitions to an early
cancer state conditioning that she has survived the current period (which occurs with
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probability ρ0t (s)), she might eventually be detected in an advanced cancer state with




probability Aat+1 ν[βt , W, ·] . However, if she transitions to an advanced cancer state,
with certainty she will eventually be detected in an advanced cancer state. If the
patient is in an early cancer state at the beginning of period t, her cancer needs to
remain undetected in the current period (which happens with probability 1 − ηt (s))
in order to be detected later in an advanced state. In such a case, if she remains in
the early cancer state, the future probability of detecting cancer in an advanced state




is Aat+1 ν[βt , W, ·] , and if she transitions to an advanced state, the corresponding
probability is one. Finally, if the patient is in an advanced cancer state, she will
eventually be detected in an advanced state with certainty.
Equations (4.4) and (4.5) respectively present the probability of eventually
detecting cancer in early and advanced cancer states starting from belief state βt at
the beginning of period t when the prescribed action is a screening mammogram with
a possible subsequent supplemental test. Note that in compliance with the breast
density notification laws, when the prescribed action is a mammogram, the patient
may take different paths depending on their observed breast density class.
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(4.4)

Equation (4.4) emerges from the following logic: If the patient is healthy, the
immediate probability of cancer detection is zero. If she is classified in the low density
class, which occurs with probability

P

θ∈Θ

QM
t (θ|d), she only receives a mammogram

test. The mammogram test result might be a true negative or a false positive with corresponding probabilities of KtM (M − |s) and KtM (M + |s), s = (0, d). In either case, if the
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patient remains in the healthy state or proceeds to early cancer state, her belief state is
updated and the future probability of cancer being detected in early state is calculated.
Note that we assume in case of a false positive, further examination (i.e, biopsy) reveals
that the patient is healthy. If the patient transitions to an advanced cancer state, her
future probability of being detected in an early cancer state is zero. When the patient
is classified into a high breast density class (with probability

P

θ∈Θ̄

QM
t (θ|d)), she may

undergo a supplemental screening if the mammogram result is negative. Possible
outcomes in such case are negative mammogram followed by a negative supplemental
test (true negative with probability KtM (M − &S − |s)), negative mammogram followed
by a positive supplemental test (false positive with probability KtM (M − &S + |s)), or
a positive mammogram (false positive with probability KtM (M + |s)). In any of these
cases, if the patient does not proceed to advanced cancer state, her belief state is
updated based on the received observations and her future probability of being detected
in early state is calculated. However, if the patient proceeds to advanced cancer state,
the cancer will never be detected in early state. If the patient is in an early cancer
states at the beginning of period t, her cancer may be detected in the current period
through screening tests. Specifically, if the patient is classified as a low and high breast
density patient, the cancer may be detected in the current period with probability
KtM (M + |s) and KtM (M + |s) + KtM (M − &S + |s), s = (1, d), respectively, in which case
the patient leaves the model. However, if the screening does not reveal the cancer,
which occurs with probabilities KtM (M − |s) and KtM (M − &S − |s), s = (1, d) when the
patient is classified as low and high density class, respectively, the patient belief is
updated based on the sensitivity of screening test(s) that the patient has undergone
and the future probability of the cancer being detected in early state is calculated.
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Finally, if the patient is in an advanced cancer state at the beginning of period t, the
probability that she eventually be detected in an early cancer state is zero.
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(4.5)

Equation (4.5) follows a logic similar to that of Equations (4.3) and (4.4) and
thus is omitted for brevity.
For the boundary conditions, a healthy patient or a patient in early cancer
states can be eventually detected in either early or advanced states. The probability
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of such events are estimated using cancer progression rates and probability of showing
symptoms after period T . For a patient in advanced cancer states at time T , the cancer
will eventually be detected in the advanced states. Let γE (s) and γA (s) respectively
denote the probability of eventually detecting cancer in early and advanced states for
a patient in state s at time T . We have








γE s = (0, d) > γE s = (1, d) ,





γE s = (2, d) = 0,

d ∈ D.

(4.6)

The probabilities γA (s) are calculated using the fact that γE (s) and γA (s) are
complementary in order to exclude overdiagnosed cases.
4.3.2 Expected number of supplemental screenings
Let Vta (βt ) denote the expected number of supplemental screenings a patient
undergoes in her remaining life years when she is in belief state βt and the prescribed
action in epoch t is a. Equations (4.7) and (4.8) calculate Vta (βt ) for actions wait
and mammogram, respectively. When the prescribed action is wait, the patient may
undergo a supplemental screening when the cancer shows symptoms. Specifically, when
the patient is in state s = (h, d) ∈ Ω1 , she may develop symptoms with probability
ηt (s). In the follow-up mammogram if she is classified as a high density and receives
a negative result, she will undergo supplement test. However, if she does not show
any symptoms (with probability 1 − ηt (s)), she proceeds to the next period with
probability

P
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VtW (βt )

W
Pt (z|s) and the expected number of screening is Vt+1
(ν[βt , W, .]).
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(4.7)
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When the prescribed action is a mammogram, the patient receives a supplemental screening only if she is classified as a high density patient in the mammogram
screening and the mammogram result is negative. In such cases, she receives an
immediate cost of 1. If the supplemental test result returns positive and the patient is
actually in a cancer state, she leaves the model. In any other cases, the patient belief
state is updated based on the screening test(s) and corresponding observation she has
received and her future cost-to-go is calculated.
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(4.8)
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4.4 Parameters estimation and model validation
The data sources used to estimate the parameters of the proposed model are
presented in Table 4.1. Following the recommended screening policies in the U.S., we
use age 45 and 75 (corresponding to t = 0 and t = T = 30) as the earliest and latest
ages that a patient undergoes a breast cancer screening test. The start age of 45 is
considered based on the new ACS policy recommendation and the fact that the risk
of developing breast cancer is very small in women younger than 45 [74]. Moreover,
we assume no screening is administered after age 75 since the risks associated with
breast cancer screening outweigh its benefits in women older than 75 [90].
Table 4.1 Source of model inputs and parameters estimation
Model Parameter
Breast density state transition probabilities
Breast density observation probability matrix
Age-specific health state transition probabilities
Age and density-specific mammography specificity
Age-specific mammography sensitivity
Joint Mammogram/ultrasound sensitivity
Joint Mammogram/MRI specificity
Joint Mammogram/MRI sensitivity
Initial density belief state
Initial health belief state

Parameter Values
Table 3.2
Table B.1
Table A.4
Table B.2
Table B.3
0.885
0.77
0.95
Table B.4
Table B.5

Source
Molani [91]
Østerås et al. [92]
Maillart et al. [15], Duffy et al. [65]
Stout et al. [93]
von Euler-Chelpin et al. [94]
Devolli-Disha et al. [95]
Group et al. [96]
Çağlayan et al. [82]
Mandelblatt et al. [62]
BCSC model[97]

4.4.1 Transition probabilities
As discussed earlier, previous studies have shown that mammographic breast
density is associated with increased breast cancer risk. We estimate the age-specific
and density-specific core transition probabilities of the breast cancer natural history
model by adjusting previously estimated transition probabilities by Maillart et al. [15]
using different odds ratios. In our baseline analysis, we use odds ratio of 3.73 which
is the midpoint of the odds ratio interval, reported in the literature ([65], [66]). We

87
will perform a sensitivity analysis to investigate the impact of odds ratio on results
in Section 4.5.1. To calculate the density-specific health transition probabilities, we
adjust disease development and progression probabilities using the odds ratios of breast
cancer risk comparing high and low breast density patients and the proportion of
women in low and high breast density class. Let pαt be the proportion of women in low
breast density at age αt associated with time period t. Let It denote the general breast
cancer incidence probability (i.e., probability of going from cancer-free state to early
breast cancer state) at time t. Moreover, let Itd represent the incidence probability for
patients in breast density class d at time t. We calculate the incidence probability for
¯

d

low and high breast density at time t, denoted by It and Itd respectively, using the
following set of equations.
¯

d

It = pαt It + (1 − pαt )Itd ,

(4.9a)

¯

odds ratio =

Itd
¯
1−Itd
d

It

(4.9b)

.

d

1−It





Therefore, the core transition probability Pt s0 = (1, d0 )|s = (0, d) is calculated as P r(transition from density state d to d0 ) · Itd , where breast density transition
probabilities are adopted from previous chapter of this dissertation. The cancer
progression probabilities is calculated using a similar approach.
We estimate breast density transition probabilities using mammography screening data from Louisiana Cancer Prevention and Control Programs [4]. Patients in the
dataset are grouped into two different age categories of 40-54 and 55+ to capture the
impact of age and menopausal status on breast density. Previous studies have shown
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a significant dependency between the menopausal status and breast tissue density [98].
The dataset contains 436 patients with longitudinal breast density assessments between
2016 and 2020. Assuming that breast density is partially observable and missing
observations are ignorable, we estimated the transition probabilities using the BaumWelch method. Note that in the ignorable missingness mechanism, the probability
of missingness depends only on the observed values and not the missing values [34].
4.4.2 Observations probabilities
We estimate breast density information matrix for an average-skilled radiologist
using a previous study by Østerås et al. [92]. In their study, a number of radiologists
interpreted 537 mammogram images and reported their density classifications. The
radiologists classification results were then compared with the volumetric breast density
obtained from a commercially available software (Quantra). They reported that in
87% of the cases the clinical interpretation agreed with radiologist reports. We also
considered information matrices reflecting a perfect radiologist, and radiologists who
always downgrade and upgrade density classifications.
The health information matrix for each screening test are estimated using their
associated sensitivity and specificity. Specificity is defined as the probability of receiving
a negative result when the patient is in cancer free stage (i.e., true negative), and
sensitivity is the probability of receiving a positive result when the patient is in a cancer
state (i.e., true positive). Specifically, let senst (a|s = (h, d)) denote the sensitivity of
action a (a ∈ {M, B}) when the patient is in a cancer state (i.e., h ∈ {1, 2}) and density
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class d, and spect (a|d) denote the specificity of action a when the patient is in breast
density class d at time t. The health information matrix can be calculated as follows.
Kta a− |s = (h = 0, d) = spect (a|d),


Kta a+ |s = (h, d) = senst (a|s = (h, d)), h = 1, 2,


Kta a+ |s = (h = 0, d) = 1 − spect (a|d),


Kta a− |s = (h, d) = 1 − senst (a|s = (h, d)), h = 1, 2,


We use the cancer stage and density specific sensitivity and specificity of mammography provided in von Euler-Chelpin et al. [94] and Stout et al. [93], respectively.
The sensitivity of joint mammogram/ultrasound and mammogram/MRI are adopted
from Devolli-Disha et al. [95] and Çağlayan et al. [82], respectively. We use the
specificity of joint mammogram/MRI from Group et al. [96].
4.4.3 Initial belief state
Initial health belief state is estimated using the Breast Cancer Surveillance
Consortium (BCSC) risk model [97]. which estimates advanced breast cancer risk
based on age, ethnicity, family history of breast cancer, history of a breast biopsy,
and BI-RADS breast density [97]. To estimate the early breast cancer risk, we
use the breast cancer stage distribution by race reported by the ACS [13], and the
race distribution in the U.S. [99]. The ratio of early to advanced breast cancer
cases among women in the U.S. is estimated as 1.78. The initial breast density
distribution for the general population are adopted from Mandelblatt et al. [62]. We
combine health and density initial belief to calculate the patient’s initial belief state,
β0 (s) =

P(Health state h | Density state d)· P(Density state d).
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4.4.4 Model validation
To validate the estimated health transition probabilities, we calculate i) lifetime
risk of developing breast cancer, ii) five-year and ten-year risks of developing breast
cancer from the proposed model, and iii) lifetime mortality risk of breast cancer with
some adjustments to the model proposed by Molani et al. [3]. The derived lifetime risk
of developing breast cancer and mortality risk of breast cancer are compared with the
corresponding risks reported by the ACS. The derived five-year and ten-year breast
cancer risks are compared with the associated risks obtained from the BCSC risk
assessment tool. Our estimation of the lifetime breast cancer risk (12.37% for general
population) is close to the reported ACS risk of 1 to 8 women (12.5%). More specifically,
we estimate the lifetime risk of developing breast cancer as 7.56% , 17.18%, and 12.37%
for women with low and high breast density, and the general population, respectively.
The estimated five-year risk of breast cancer using the BCSC risk assessment tool at age
60 and 70 are 1.68% and 2.00%, which are comparable with our estimations of 1.59%
and 2.37%. Moreover, the ten-year breast cancer risk estimated using the BCSC risk
tool are 2.51%, 3.45%, and 3.80% at age 50, 60 and 70. These are comparable with our
corresponding estimated risks of 2.17%, 3.76%, and 4.03%, respectively. In addition, we
estimate the lifetime breast cancer mortality risk under several screening policies (see
Table 4.2) for the general population (average-risk). The average of lifetime mortality
risks across all policy equals 2.88% which is comparable with the reported ACS risk of
1 to 38 women (2.63%) [100]. Note that we report the average lifetime breast cancer
mortality risk across different policies (screening frequencies) to implicitly account
for the variation in the breast cancer screening frequencies for women in the U.S.
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4.5 Numerical analyses
In this section, we evaluate the efficacy of supplemental screening and the
impact of radiologists bias on patients outcomes for some of the in-practice screening
policies. Table 4.2 presents the policies, denoted by P1 through P7, evaluated in this
study. The screening policies recommended by the two major U.S. health agencies, the
ACS and USPSTF, along with some screening guidelines in the European countries
are evaluated. These policies differ in terms of recommended screening starting and
stopping ages and the screening interval. Biennial and triennial screening with starting
and stopping age of 45 and 75, respectively, are also assessed. Additionally, we consider
do nothing (DN) policy with no recommended screening test in a patient lifetime.
Table 4.2 Screening policies considered in the numerical analysis
Policy ID

Institution/Policy

Start age

End age

P1
P2
P3
P4
P5

The annual option of the ACS policy (2015)
The ACS policy with switching interval (2015)
Biennial screening between age 45 and 75
Triennial screening between age 45 and 75
USPSTF (2016), AAFP (2016), France and Netherlands
Belgium, Denmark, Finland, Germany, Ireland,
Poland and Spain
United Kingdom

45
45
45
45
50

75
75
75
75
74

50

69

NA

NA

2

2

50

70

NA

NA

3

3

P6
P7

Screening Interval
40-44 45-49 50-54 55+
NA
1
1
1
NA
1
1
2
NA
2
2
2
NA
3
3
3
NA
NA
2
2

In our numerical analyses, patients are classified into two classes of low and
high density where the former includes BI-RADs density classification of almost
entirely fatty and scattered fibroglandular and the latter includes heterogeneously
dense and extremely dense classes. This is because per the breast density notification
law, patients follow the same guideline weather they are in breast density class 3
or 4. Classifying patients into two density groups also reduces the computational
complexity, especially for policies with high number of prescribed screenings.
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We consider 4 different radiologist types: radiologist with minimizing reporting
requirement behavior (type 1), average-skilled radiologist (type 2), perfect radiologist
(type 3), and radiologist with minimizing liability behavior (type 4). Radiologists type
1 and 4, always downgrad and upgrade patients breast density categories, respectively.
Note that under radiologist type 1, the patient never undergoes a supplemental
test while under radiologist type 4, all screening mammograms are followed by a
supplemental test. Radiologist type 3 (perfect radiologist) classifies breast density
with 100% accuracy and radiologist type 2 (average-skilled) has 13% missclasisfication
probability [92], as discussed in Section 4.4.2.
Four patient cases differing in breast cancer risk characteristics including race,
breast density, breast cancer family history, and biopsy history are considered. The
initial belief for these patients are calculated using the BCSC risk model, described
in Section 4.4.3. These cases are as follows:
Case 1 : A 45-year-old white woman with no breast cancer family history or prior
biopsy. It is assumed that this case is in density class 1 at age 45. This patient is
considered to be a low risk case with initial (at age 45) estimated early and advanced
breast cancer risks of 0.28% and 0.16% .
Case 2 : All risk factors for this case are similar to Case 1, except for the initial
breast density which is assumed extremely dense. This patient’s risks of being in
early and advanced breast cancer states at age 45 are estimated as 1.19% and 0.67%,
respectively.
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Case 3 : A 45-year-old white woman with a family history of breast cancer and
prior biopsy and breast density class of 4. The patient’s estimated risks of early and
advanced breast cancer at age 45 are estimated as 16.38% and 9.2%, respectively.
Case 4 : This case represents the general population. The estimated risks of early
and advanced breast cancer for average-risk population at age 45 are 1.67% and 0.94%,
respectively [101]. Using the breast density distribution of the women population in
the U.S. provided by [62], we estimate the initial belief state for this case.
Figures 4.2 and 4.3 present the probability of detecting cancer in early and
advanced states and the expected number of supplemental screening tests for different
radiologist types when ultrasound and MRI are used as supplemental screening tests,
respectively. Note that under radiologists with minimizing reporting requirement behavior, patients undergo only mammogram tests. Obviously, more aggressive screening
strategies are more likely to detect the cancer in early states, where there is a higher
chance of survival. That is, 1) the ACS policy with fixed screening intervals has the
highest probability of detecting cancer in early states for all four cases and all radiologist
types. 2) Under radiologist type 4 where patients always undergo supplemental screenings, patients receive the highest probability of being detected in early cancer state.
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Figure 4.2: Lifetime probabilities of detecting cancer in early and advanced states and
expected number of supplemental tests under different radiologist types–supplemental
test: ultrasound
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Figure 4.3: Lifetime probabilities of detecting cancer in early and advanced states and
expected number of supplemental tests under different radiologist types–supplemental
test: MRI
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Moreover, the results suggest that in terms of the probability of detecting
cancer in early states, the difference in performance of perfect and average-skilled
radiologists is very small. In fact, the performances of perfect and average-skilled
radiologists are very close to the performance of radiologist type 4. However, note
that the radiologist type 4 impose a significantly higher number of supplemental
screening tests on patients. For example, for Case 1, who would not really benefit
from supplemental screening since she most likely remains in low breast density in her
lifetime, the expected number of supplemental tests that she undergoes are 23.85 and
16.97 under the two ACS policies. Under the perfect radiologists, the expected number
of supplemental screening tests are 0.41 and 0.36. Note that this implies that the
patient undergoes 23.44 and 16.61 unnecessary supplemental tests under radiologist
type 4 which adversely affect her quality of life. Under the average-skilled radiologist,
the expected number of supplemental tests are 3.41 and 2.48 for the two ACS policies,
which suggests that the unnecessary number of supplemental tests are 3.00 and 2.12,
respectively. The expected number of unnecessary supplemental tests are smaller
under the other screening policies as they are less aggressive. This implies that averageskilled radiologists performance is very close to perfect radiologists performance when
comparing the probability of detecting cancer in early state. However, in terms of the
expected number of supplemental tests, the difference might be significant (depending
on the aggressiveness of screening polices).
The differences in the performance of radiologists become more evident as the
patient’s risk increases. That is, for Case 1 and Case 3 the differences are at their
lowest and highest level, respectively. Specifically, for Case 1 and under ultrasound as
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the supplemental test, the probability of detecting the cancer in early state increases
by only 0.63%, 1.11% for the ACS policies (P1 and P2) when going from radiologist
type 1 to type 4. For Case 3, under radiologist type 4, the probability of detecting
breast cancer in early states for the two ACS policies are 84.95% and 83.83%, as
compared with 73.91% and 72.30% corresponding to radiologist type 1 (a difference of
11.04% and 11.52%, respectively). Case 2 and 4 fall in between Case 1 and 3, with a
slightly higher increase in probability of detecting cancer in early state when going
from radiologist type 1 to type 4 (i.e., an increase between 1.83% and 3.15%).
This also implies that the efficacy of supplemental screening highly depend on
the patients’ overall breast cancer risk and not only their breast density. For patients
with a lower risk (e.g., Case 1 ), the benefits of undergoing supplemental screening is
minimal, as discussed above. For Case 2 with all risk factors similar to Case 1 but
breast density, we observe an increase in early state probability detection when she
undergoes supplemental test. For instance, under mammogram only policy (radiologist
type 1), the early detection probability is 92.75% for policy P1 and this probability
increases to 94.89% and 95.00% under radiologist type 2 and 3 who recommend patient
undergo ultrasound test as needed, per breast density notification law. For Case 3,
however, undergoing ultrasound screening provide a significantly higher benefit, as
discussed above.
Comparing MRI and ultrasound, we observe that MRI always results in a
higher probability of detection in early state as it is more sensitive than ultrasound.
The difference, although, is negligible, especially for low risk cases. The highest
difference in performance of MRI and ultrasound occurs for Case 3. For this case,
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under the average-killed radiologist and biennial and triennial screening policies, using
MRI results in corresponding early detection probabilities of 81.85% and 78.56%,
as compared with 78.76% and 74.61% when undergoing ultrasound. On the other
hand, MRI imposes slightly lower expected number of supplemental test compared
to ultrasound. Note that MRI is a more aggressive test and therefore it might be
beneficial to be used only for the cases with higher risk such as Case 3.
The results show that in general, policies that recommend starting screening at
age 45 outperform those with starting age of 50. That is because breast cancer is more
aggressive at younger ages. The impact of starting age in particular and screening
policy in general on detecting cancer in early states is specifically very evident for
Case 3. This implies that the probability of detecting cancer in early states is more
impacted by the policy type and patient risk than the radiologist type.
All in all, the results show that 1) breast density is not a sufficient factor when
administering supplemental screening as the increases in probabilities of detecting
cancer in early states in all cases expect for Case 3 are very negligible among different
radiologist types for any given policy. Other risk factors must be taken into account
when recommending a supplemental screening (as shown in Case 3 ). 2) Average and
perfect radiologists performance are very similar and comparable to the performance
of radiologist type 4. Additionally, if the patient is not a high risk case, radiologist
type 1 performance is also comparable to the other radiologist types. This implies
that radiologist type impact is not as significant as other factors such as the patient
risk factors and screening frequency.
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4.5.1 Sensitivity analyses
In this section, we conduct sensitivity analyses on 1) odds ratio (OR) of
breast cancer risk comparing women in different density classes and 2) sensitivity and
specificity of supplemental screening and probability of cancer showing symptoms.
These parameters are selected due to the variability in their reported values in the
literature. We consider 4 different ORs, excluding the baseline OR. In the second
part of sensitivity analyses, we consider 18 different combinations for sensitivity and
specificity of the supplemental test and the probability of the cancer showing symptoms.
In total, for each patient case, we evaluate the outcomes under 832 settings.
Odds ratios
Based on the previous studies, the odds ratio for developing breast cancer for
the most dense compared with the least dense breast tissue categories ranges from
1.46 to 6.0 [65, 66]. We use the midpoint value (OR=3.73) in our baseline analyses,
presented in Figures 4.2 and 4.3. Here, we consider OR values of 1.46, 2.595, 4.865,
and 6. These ORs are selected to include minimum and maximum values reported
in the literature, as well as the midpoints values of the intervals formed by these
values and the baseline OR. Note that as the OR increases, the breast cancer risk gap
between women with high and low breast density increases.
Figure 4.4 presents the change in the early detection probability caused by
a change in OR values, when compared to the baseline. Note that negative and
positive changes present a decreased and an increased probability of early detection,
respectively.
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Figure 4.4: Results of sensitivity analyses on odds ratio of breast cancer comparing
fatty and extremely dense classes. Note that negative/positive values imply
decreased/increased probability of detecting cancer in early states compared with the
baseline (OR = 3.73)
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Under the maximum OR value (OR = 6), we observe an average absolute
change of 1.08% across all cases, radiologist types and policies, with a maximum of 4.5%
(under Case 1, radiologist type 1, and do nothing policy). Under increased OR, patients
with low breast density (e.g., Case 1 at age 45) carry lower breast cancer incidence
and progression rates compared to the baseline. On the other hand, patients with high
breast density (e.g., Case 2 at age 45) carry higher breast cancer risk. Interestingly, the
results suggest that for both of these cases, the probability of early detection increases
(except for Case 2 under do nothing policy.) This is expected for Case 1 as this case
starts and most likely remains in density class 1 in her lifetime. For Case 2, the increase
in detection probability seems counter-intuitive since this case has an increased breast
cancer risk due to occupying density class 4. However, note that the increase in early
detection probability is very negligible and due to probable transition of this patient
to a low density class over the course of few epochs. Note that, based on our data and
previous studies, breast density stochastically decreases over time [67, 68, 69]. For
the other two cases, the changes are very negligible, especially for Case 3. Obviously,
under OR value of 4.865, the changes are smaller but follow similar patterns.
With a decreased OR, we observe a higher changes in probability of early
detection. Specifically, under OR value of 1.46, we observe a maximum change of
12.72% (for Case 1 under do nothing policy). In general, we observe a decrease in
probability of early detection for Case 1, 2, and 4 (except for do nothing policy for
Case 2 ). Note that with a decreased OR, patients with lower breast density carry
higher risk compared with the baseline which results in a decrease in probability of
early detection. Under do nothing policy for Case 2, we observe a very negligible
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change in early detection probability. Note that the small change in this case is mainly
contributed by the patient’s belief of being in cancer state. The patient’s cancer belief
under this policy is generally higher due to lack of screening tests and consequent less
informative risk adjustments of the patient. This is also true for Case 3 whose change
in early detection probability is very negligible for do nothing policy and screening
policies starting at age 50.
Generally, with increased/decreased OR we observe an increase/decrease in
early detection probability. The magnitude of changes, however, vary across different
patients and screening policies. The results, in general, are consistent and prompt
comparable conclusions with those derived under the baseline OR.
Supplemental test accuracy and probability of cancer symptoms
We consider 3 different levels of sensitivity and 3 different levels of specificity
for supplemental screening test. We also consider 2 different levels for the probability
of showing symptoms. Using a full factorial design, we have 18 different combinations
for these parameters. We consider 1) joint sensitivity of mammogram and ultrasound
decreased by 5%, 2) joint sensitivity of mammogram and MRI increased by 5%, and
3) the midpoint of the interval formed by the joint mammogram/ultrasound and
mammogram/MRI sensitivity values in the baseline. Similarly, we calculate three
levels for supplemental screening specificity. We consider 5% increase and decrease in
the baseline probability of showing symptoms.
Figure 4.5 presents the change in the probability of detecting cancer in early
state for Case 3 under average-skilled radiologist. We present the results only for
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Case 3 for brevity; however, note that in general, sensitivities to parameters changes
are smaller for the other cases. For example, the maximum change in the probability
of detecting cancer in early states for Case 1 is only 1.57% when compared with the
baseline. The maximum change for Case 3 is 8.44%.
Obviously, the changes in sensitivity of testing has the highest impact on the
probabilities of early detection. As the test sensitivity increases, the probability of
detecting cancer in early state increases. The increase in early detection probability is
smaller for policies with more frequent screening policies as more frequent screenings
compensate for possible false negatives. The increase is at the highest for policy P4,
due to the longer intervals between subsequent recommended screening tests (3 years).
Note that for policy P7, although following the same screening frequency, the change
is very small due to the delayed screening start age. That is, it is very likely that the
cancer remains undetected and grows to advanced state between age 45 and 50 which
consequently decreases the chance of detecting the cancer in early states. Recall that
Case 3 is a high risk case and has an aggressive breast cancer.
Similarly, increasing the probability of showing symptoms results in an increase
in the probability of detecting cancer in early states. The highest impact is associated
with less aggressive policies. For instance, for Case 3 and under do nothing policy, we
observe an increase of 3.86% in the probability of early detection when increasing the
probability of showing symptoms. On the other hand, for the ACS policy with fixed
screening interval (P1), we observe the lowest sensitivity to the probability of showing
symptoms, with an average increase of 1.43% across different sensitivity analyses
combinations considered here.
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Specificity of screening tests has an opposite impact on the probability of
detecting cancer in early states. That is, increased joint specificity causes a decrease
in the probability of early detection. This happens as with increased joint specificity,
the number of false positive observations, resulting in consequent biopsies, decreases.
Recall that biopsies are perfect and determine with certainty that the patient is cancer
free. This causes an overall decrease in the belief that the patient is in cancer states
and the probability of detecting cancer in early state.
In summary, the sensitivity of joint mammogram and supplemental test has
the largest and the specificity of joint mammogram and supplemental test has the
smallest impact on the probability of early detection. The conclusions in the baseline
analyses still hold. That is, as long as a supplemental test is administered for a patient
(radiologist types 2–4), a bias in radiologist’s classification has a negligible impact on
the probability of detecting cancer in early states. That is, under the same policy, the
difference in the probabilities of early detection across radiologists type 2 through 4
is minimal. Moreover, breast density should not be the sole determining factor as
whether a patient should be referred to supplemental screening tests. Other breast
cancer risk factors and frequency of screening tests should be considered when making
such referrals.
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Figure 4.5: Results of sensitivity analyses on joint mammogram and supplemental
test sensitivity and specificity and the probability of showing symptoms: Case 3 and
average-skilled radiologist
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4.6 Conclusion
Breast density is associated with increased breast cancer risk and decreased
mammography screening sensitivity. To promote early breast cancer detection in
women with high breast density, breast density notification laws have been enacted
in 38 states. The laws, however, have caused controversial debates on 1) whether
supplemental screening improves patients’ outcomes and 2) the impact of radiologists
bias in breast density classification on patient’s outcomes.
In this study, we develop a POMC model, incorporating both patients’ health
and breast density dynamics, to investigate the impact of supplemental screening tests
and role of radiologists’ bias on a patients’ health outcomes. Specifically, we consider
the conditional probability of detecting breast cancer in early and advanced states
given the patient develops cancer in her lifetime. We consider the expected number
of supplemental tests a patient undergoes in her lifetime as another outcome.
Our results indicate that 1) breast density should not be the only risk factor
when referring a patient to supplemental screening and 2) the radiologist’s bias may
affect the efficacy of supplemental screening. Specifically, patient outcomes may be
significantly affected under radiologists who consistently upgrade or downgrad patient’s
breast density. However, the bias introduced by an average-skilled radiologist may
not significantly affect the patients’ outcomes.
Given that screening technologies are continuously advancing, a possible future
research direction would be to analyze the impact of emerging technologies (e.g.,
tomosynthesis) on the necessity of supplemental screening tests for women with high
breast density. Moreover, patients’ adherence is a very influential factor on the

107
effectiveness of a screening policy and patients’ outcomes that is not considered in
this study. A possible future work is to incorporate this factor.

CHAPTER 5
CONCLUSIONS
This dissertation proposed and investigated the use of stochastic decision
models in breast cancer preventive care. We addressed several controversial issues in
breast cancer screening programs, including overdiagnosis risk and the implications of
use of supplemental screening test in breast ccancer preventive care.
In chapter 2, we use two stochastic frameworks for the patient’s adherence and
the breast cancer natural history to estimate different measures of overdiagnosis risk
of mammography screening while incorporating uncertainty in patients’ adherence
behaviors. The measures of overdiagnosis risk investigated in this study include
the proportion of detected cancers that are overdiagnosed in a screened population,
mortality risk considering overdiagnosis, and overtreatment costs. We analyze the
harm-benefit trade-off of some in-practice policies by measuring the number of lives
that are saved per each overdiagnosed case. We also estimate the associated proportion
of overtreatment cost to breast cancer care cost for each policy. Our results show that,
although overdiagnosis rate is relatively high in breast cancer screening, the benefits
of breast cancer mammography screening outweigh the overdiagnosis risk.
In chapter 3, we reviewed several methods to estimate Markov model parameters using a set of data with intermittent missing values. We discussed three
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categories of methods for datasets with ignorable missingness mechanism including
deletion, imputation, and augmentation. Moreover, we executed a frequentist setting
(Expectation-Maximization algorithm) and a Bayesian framework (Gibbs Sampler)
on several simulated data to measure the bias of the results from each algorithm.
Finally, we used Baum-Welch algorithm on a set of sparse unbalanced data consist of
hidden observations for breast density states of a group of patients at Louisiana Cancer
Prevention and Control center. Estimated breast density transition matrices specify a
relatively high probability that successive observations recur. This implies that future
outcome has a high dependency on the current outcome. The results of this chapter
were used in chapter 4 where we developed a POMC model to investigate the impact
of the radiologists’ expertise level and behavior on the implementation of the breast
density notification law and their implications on patients’ health outcomes. The
efficacy of ultrasound and MRI as supplemental screening methods are also studied
under implementation of the density notification laws. The patients’ outcome measures
investigated in this chapter include the lifetime probability of detecting cancer in early
and advanced cancer states in the population of patients who would eventually develop
cancer at some point in their lifetime and expected number of required supplemental
screening for each policy under radiologists with different level of expertise and different
supplemental screening. Based on our results, referring patients to a supplemental test
solely based on their breast density may not significantly improve patient’s outcomes
and other risk factor might be considered when making such decision. Additionally,
average-skilled radiologists performance are comparable with a perfect radiologist
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performance. However, significant bias (i.e., consistent upgrading and downgrading of
breast density classes) can negatively impact a patient health outcomes.
Some possible future works include:
• Development of models to determine race-specific overdiagnosis risk given the
disparity in incidence and mortality among different races.
• Development of an optimization model to derive optimal screening policy that
controls the risk of overdiagnosis.
• Implementation of Markov model parameter estimation methods on a larger
breast density dataset with more number of observations for each patient to
reduce the bias of these estimations.
• Analyzing the impact of emerging technologies (e.g., tomosynthesis) on the
necessity of supplemental screening tests for women with high breast density.
• Considering patients’ adherence as an influential factor on the effectiveness of a
screening policy and patients’ outcomes in analyzing the effectiveness of breast
density notification law.

APPENDIX A
PARAMETER VALUES FOR CHAPTER 2
Table A.1 Adherence state transition probabilities
Time t+1
40-49 years

50-64 years

65+ years

Time t

Regular

Irregular

Regular

Irregular

Regular

Irregular

Regular

0.7627

0.2372

0.7299

0.2700

0.7429

0.2570

Irregular

0.3837

0.6162

0.2356

0.7643

0.1440

0.8559

Table A.2 Adherence rates
40-49 years

50-84 years

85-100 years

Regular screening

0.9014

0.9551

0.8924

Irregular screening

0.2914

0.2619

0.0603

Table A.3 Initial adherence belief

Initial adherence belief

Regular screening

Irregular screening

0.2309

0.7691
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Table A.4 Health state transition probabilities

Time t
s1
s2
s3
s4
s5
s6

Time t + 1
s1
s2
s3
s4
40-44 years
0.99784 0.000975
0
0
0
0.7309
0.26792
0
0
0
0.928548 0.070272
0
0
0
0.8442
0
0
0
0
0
0
0
0

s5

s6

0
0
0
0.15462
1
0

0.00118
0.00118
0.00118
0.00118
0
1

s1
s2
s3
s4
s5
s6

45-49 years
0.99703 0.001281
0
0
0
0.7309 0.267409
0
0
0
0.928037 0.070272
0
0
0
0.8442
0
0
0
0
0
0
0
0

0
0.001691
0
0.001691
0
0.001691
0.154109 0.001691
1
0
0
1

s1
s2
s3
s4
s5
s6

50-54 years
0.99563 0.001682
0
0
0.7309
0.26641
0
0
0.927038
0
0
0
0
0
0
0
0
0

0
0
0.070272
0.8442
0
0

0
0
0
0.15311
1
0

0.00269
0.00269
0.00269
0.00269
0
1

s1
s2
s3
s4
s5
s6

55-59 years
0.99371 0.00198
0
0.7309
0
0
0
0
0
0
0
0

0
0
0.264786
0
0.925414 0.070272
0
0.8442
0
0
0
0

0
0
0
0.151486
1
0

0.004314
0.004314
0.004314
0.004314
0
1

s1
s2
s3
s4
s5
s6

60-64 years
0.99086 0.002214
0
0
0
0.7309 0.262173
0
0
0
0.922801 0.070272
0
0
0
0.8442
0
0
0
0
0
0
0
0
Continued on next page

0
0.006927
0
0.006927
0
0.006927
0.148873 0.006927
1
0
0
1
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Table A.4 Health state transition probabilities - Countinued . . .

s1
s2
s3
s4
s5
s6

s1
s2
s3
s4
65-69 years
0.98656 0.002377
0
0
0
0.7309 0.258036
0
0
0
0.918664 0.070272
0
0
0
0.8442
0
0
0
0
0
0
0
0

0
0.011064
0
0.011064
0
0.011064
0.144736 0.011064
1
0
0
1

s1
s2
s3
s4
s5
s6

70-74 years
0.97945 0.002509
0
0
0
0.7309 0.251055
0
0
0
0.911683 0.070272
0
0
0
0.8442
0
0
0
0
0
0
0
0

0
0.018045
0
0.018045
0
0.018045
0.137755 0.018045
1
0
0
1

s1
s2
s3
s4
s5
s6

75-79 years
0.96702 0.0024
0
0.7309
0
0
0
0
0
0
0
0

0
0.030581
0
0.030581
0
0.030581
0.125219 0.030581
1
0
0
1

s1
s2
s3
s4
s5
s6

80-84years
0.92519 0.002075
0
0
0.7309
0.19636
0
0
0.856988
0
0
0
0
0
0
0
0
0

0
0
0.070272
0.8442
0
0

0
0
0
0.08306
1
0

0.07274
0.07274
0.07274
0.07274
0
1

s1
s2
s3
s4
s5
s6

85-90 years
0.92519 0.002075
0
0
0.7309
0.19636
0
0
0.856988
0
0
0
0
0
0
0
0
0

0
0
0.070272
0.8442
0
0

0
0
0
0.08306
1
0

0.07274
0.07274
0.07274
0.07274
0
1

Continued on next page

0
0
0.238519
0
0.899147 0.070272
0
0.8442
0
0
0
0

s5

s6
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Table A.4 Health state transition probabilities - Countinued . . .

s1
s2
s3
s4
s5
s6

s1
90-94
0.92519
0
0
0
0
0

s1
s2
s3
s4
s5
s6

95-100
0.92519
0
0
0
0
0

s2

s3

s4

s5

s6

0.002075
0
0.7309
0.19636
0
0.856988
0
0
0
0
0
0

0
0
0.070272
0.8442
0
0

0
0
0
0.08306
1
0

0.07274
0.07274
0.07274
0.07274
0
1

0.002075
0
0.7309
0.19636
0
0.856988
0
0
0
0
0
0

0
0
0.070272
0.8442
0
0

0
0
0
0.08306
1
0

0.07274
0.07274
0.07274
0.07274
0
1

Table A.5 Mammography sensitivity
Early breast cancer

Mammography sensitivity

Advance breast cancer

40-49

50+

40-49

50+

0.75033

0.85449

0.81860

0.93224

Table A.6 Initial health belief
Healthy

Early breast cancer

Advance breast cancer

0.997

0.0006

0.0024
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Table A.7 Survival rate for screen-detected breast cancer by state
State

Survival probabilities

Healthy to Healthy

0.99

Healthy to Early

0.004

Early to Early

0.7309

Early to Advanced

0.263

Advanced to Symptomatic

0.0703

Advanced to Advanced

0.923

Table A.8 U.S. age composition
Age groups

Population by age

Age groups

Population by age

40-44 years

10,496,987

70-74 years

5,034,194

45-49 years

11,499,506

75-79 years

4,135,407

50-54 years

11,364,851

80-84 years

3,448,953

55-59 years

10,141,157

85-89 years

2,346,592

60-64 years

8,740,424

90-94 years

1,023,979

65-69 years

6,582,716

95-99 years

288,981

Table A.9 Breast cancer treatment costs
Cost
Early breast cancer treatment

$ 32103

Advance breast cancer treatment

$ 51837

Screening

$ 102

APPENDIX B
PARAMETER VALUES FOR CHAPTER 4
Table B.1 Breast density observation probability matrices
Observed state
Low density
True state

High density

Radiologist with Min. Reporting Requirement

Low density

1

0

High density

1

0
Average-Skilled Radiologist

Low density

0.87

0.13

High density

0.13

0.87
Perfect-skilled Radiologist

Low density

1

0

High density

0

1
Radiologist with Min. Liability

Low density

0

1

High density

0

1
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Table B.2 Age and density-specific mammography specificity
Age groups
Breast density 45-49

50-54

55-60

60-64

65-69

70-74

75-79

0.917585

0.917988

0.918083 0.918201

Low density

0.901563 0.916036

0.916889

High density

0.866351

0.888364 0.887937 0.887579 0.88737

0.889283

0.887407

Table B.3 Density-specific mammography sensitivity
Low breast density

High breast density

0.765

0.58

Mammography sensitivity

Table B.4 Initial density belief state
Age groups
Breast density

40-44

45-49

50-54

55-59

60-64

65-69

70-74

75-79

dI

0.046

0.055

0.075

0.098

0.117

0.13

0.136

0.139

dII

0.338

0.364

0.422

0.471

0.5

0.521

0.537

0.539

dIII

0.472

0.458

0.416

0.373

0.338

0.313

0.296

0.291

dIV

0.144

0.123

0.086

0.058

0.045

0.036

0.031

0.031

Table B.5 Initial health belief state
Health state
Patient

Cancer free

Early breast cancer

Advance breast cancer

Case 1

0.995552

0.002848

0.0016

Case 2

0.981374

0.011926

0.0067

Case 3

0.74424

0.16376

0.092

Case 4

0.973868

0.016732

0.0094

APPENDIX C
DATA PRE-PROCESSING
In Chapter 3, we applied several hidden Markov model parameter approximation
methods to estimate breast density transition probabilities using mammography
screening data from Louisiana Cancer Prevention and Control Programs [4]. This
longitudinal data has been gathered from 436 patients since 2016 and sent as the
physical reports. These reports contained information such as the age of the patient,
BI-RADS health and breast density state of the patient, date of screening, radiologist
name, and the future recommendation for the patient. The first data preprocessing
step was to convert these text files to excel worksheets manually.
In addition, the dataset contains missing values which comes from the missed
scheduled visits of patients for evaluation of their health and breast density status. We
assume the missingness mechanism in this dataset is ignorable since the probability of
a patient shows up for breast screening mostly depends on their previous screening
results rather than current observation. This comes from the fact that the symptomatic
breast cancer usually happens at the very advanced stage of a cancer, which means
that patients who show up for screening are mostly because of previous suspicious
results or to follow-up the screening policy recommendation. In the next step, we
divided observations based on the age of patients into two groups (40 − 55/55+) in
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order to consider the age and menopause effects on breast density dynamics in our
analysis. A small section of this dataset is presented below.
Table C.1 A sample of dataset for estimation of breast density dynamics
ID

Date of birth

Date of screening

Age

Density state

Health state

Future recommendation

Radiologist

332398

11/27/1953

04/05/2016

62

dII

2

Screening in 1 year

MBM

332398

11/27/1953

11/06/2017

64

dII

2

Screening in 1 year

MBM

424266

10/23/1956

01/22/2016

59

dI

1

Screening in 1 year

MBM

424266

10/23/1956

11/07/2017

61

dI

1

Screening in 1 year

MBM

415831

08/08/1951

01/20/2015

63

dIII

2

Screening in 1 year

MBM

415831

08/08/1951

06/19/2015

64

dIII

2

Screening in 1 year

LFSR

415831

08/08/1951

08/26/2016

65

dIII

2

Screening in 1 year

BLM

415831

08/08/1951

11/07/2017

66

dII

2

Screening in 1 year

MJM

624400

06/28/1970

11/01/2016

46

dIII

2

Screening in 1 year

BLM

624400

06/28/1970

11/07/2017

47

dIII

2

Screening in 1 year

MJM

298288

11/23/1950

10/12/2016

66

dII

2

Screening in 1 year

BLM

298288

11/23/1950

11/08/2017

67

dI

2

Screening in 1 year

MJM

390921

08/12/1960

11/04/2016

56

dII

1

Screening in 1 year

BLM

390921

08/12/1960

11/08/2017

57

dII

1

Screening in 1 year

MJM

APPENDIX D
PSEUDO-CODES
D.1 Codes for Chapter 2
Algorithm 1: Calculate patient’s adherence-health belief state
t ← 0;
while t <= T do
t ← t + 1;
if at == W then
κht+1 (s0b ) ← κ[κht , W, ·](s0b );
ηχt+1 (s0h ) ← τ [ηχt , W, ·](s0h );
else
κht+1 (s0b ) ← κ[κht , M, ot ](s0b );
ηχt+1 (s0h ) ← τ [ηχt , M, θt ](s0h );
end
end

Algorithm 2: Calculate patient’s outcomes in Chapter 2
t ← T;
while t => 0 do
t ← t − 1;
if at == W then
Calculate ψtW (ηχt ) using Equation 2.14 recursively;
else
Calculate ψtM (ηχt ) using Equation 2.15 recursively;
end
end
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D.2 Codes for Chapter 3
Algorithm 3: Baum-Welch Algorithm
Initialize;
for ν = 0 do
Select λ(0) = (π (0) , B (0) , A(0) );
end
Iterative calculation ;
for ν = 1, 2, · · · do
πiν

←

PΓ
γ ν (i)
PΓ η=1
PS η,1 ν
η=1

aνij

←

i=1

γη,1 (i)

;

PΓ PT −1 ν
ξη,t (i,j)
Pη=1
Pt=1
;
Γ
T −1 ν
η=1

bi (j)ν ←

t=1

γη,t (i)

PΓ PT ν
γη,t (i)δ(yη,t =j)
Pη=1
Pt=1
;
Γ
T
ν
η=1

t=1

γη,t (i)δ(yη,t 6=.)

where,
αη,t (i) ← P (Yη,1 = yη,1 , ..., Yη,t = yη,t , sη,t = i|λ)
βη,t (i) ← P (Yη,t+1 = yη,t+1 , ...Yη,T = yη,T |sη,t = i, λ)
αη,t (i)βη,t (i)
γη,t (i) ← P
S
j=1

ξη,t (i, j) ←

αη,T (j)

αη,t (i)aij bj (yη,t+1 )βη,t+1 (j)

PS
i=1

αη,T (i)

end
Termination;
Obtain λν+1 = (π ν+1 , B ν+1 , Aν+1 )
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D.3 Codes for Chapter 4
Algorithm 4: Calculate patient’s density-health belief state
t ← 0;
while t <= T do
t ← t + 1;
if at == W then
βt+1 ← ν[βt , W, ·](z);
else
βt+1 ← ν[βt , M, ot ](z);
end
end

Algorithm 5: Calculate patient’s outcomes in Chapter 4
t ← T;
while t => 0 do
t ← t − 1;
if t == T then
Calculate γE (s) and γA (s) using cancer progression rates and
probability of showing symptoms after period T
else
if at == W then
Calculate EtW (βt ) using Equation 4.2 recursively;
Calculate AW
t (βt ) using Equation 4.3 recursively;
W
Calculate Vt (βt ) using Equation 4.7 recursively;
else
Calculate EtM (βt ) using Equation 4.4 recursively;
Calculate AM
t (βt ) using Equation 4.5 recursively;
M
Calculate Vt (βt ) using Equation 4.8 recursively;
end
end
end
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